返回工具

数据核查

公司年份 百万美元较上年变化,% 等级报告值来源位置备注
argenx2025 4151 – B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
BioNTech2022 3339 – B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
CJ第一制糖2015 3228 – B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CJ CheilJedang ... 3,228" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
CSL2000 582 – C 1,000 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1000 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2001 620 6.7 C 1,200 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1200 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2002 761 22.7 C 1,400 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1400 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2003 1109 45.7 C 1,700 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2004 1326 19.6 C 1,800 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2005 1525 15.0 C 2,000 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2000 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2006 1658 8.7 C 2,200 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2200 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2007 2097 26.5 C 2,500 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2500 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2008 2642 26.0 C 3,100 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2009 3248 22.9 C 4,100 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4100 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2010 4050 24.7 C 4,400 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4400 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2011 4751 17.3 C 4,600 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4600 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2012 5181 9.0 C 5,000 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5000 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2013 4875 -5.9 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 4,875" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
CSL2014 4743 -2.7 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 4,743" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
CSL2015 6294 32.7 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 6,294" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
CSL2016 6674 6.0 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 6,674" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
CSL2017 7522 12.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 7,522" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
CSL2018 8270 9.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 8,270" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
CSL2019 8951 8.2 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 8,951" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
CSL2020 9656 7.9 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
CSL2021 10444 8.2 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
CSL2022 13123 25.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
CSL2023 14176 8.0 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
CSL2024 15009 5.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
CSL2025 15441 2.9 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Horizon Therapeutics2022 4022 – B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Novavax2022 1555 – B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
三共2004 4051 – B 435,140 JPY m phx_dsc_pres+phx_daiichi_20f+fx_fed_h10 Daiichi Sankyo merger presentation, FY2004 combined pharma figure
Pharmaceutical net sales: combined Sankyo + Daiichi Pharm...Pharmaceutical net sales: combined Sankyo + Daiichi Pharmaceutical (760 bn yen) minus Daiichi Pharmaceutical (324.9 bn)
760,000 - 324,860 = 435,140; Sankyo total net sales 587,830 incl. non-pharma
The 760 bn combined figure was quoted in a search result for a Daiichi Sankyo investor presentation; document not opened.
三菱化学集团2023 4235 – B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
上海医药2000 83 – C 690 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2000-12-31
Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 460,072.38" (10,000 CNY) = 4,600.72 m x 15% = 690.11 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2001 94 13.3 C 782 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2001-12-31
Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 521,059.32" (10,000 CNY) = 5,210.59 m x 15% = 781.59 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2002 131 39.1 C 1,088 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2002-12-31
Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 725,045.56" (10,000 CNY) = 7,250.46 m x 15% = 1,087.57 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2003 178 35.2 C 1,470 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2003-12-31
Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 980,255.52" (10,000 CNY) = 9,802.56 m x 15% = 1,470.38 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2004 197 10.6 C 1,627 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2004-12-31
Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 1,084,383.04" (10,000 CNY) = 10,843.83 m x 15% = 1,626.57 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2005 196 -0.1 C 1,608 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2005-12-31
Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 1,072,286.69" (10,000 CNY) = 10,722.87 m x 15% = 1,608.43 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2006 238 21.1 C 1,896 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2006-12-31
Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 1,263,916.73" (10,000 CNY) = 12,639.17 m x 15% = 1,895.88 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2007 275 15.5 C 2,088 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2007-12-31
Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 1,391,979.12" (10,000 CNY) = 13,919.79 m x 15% = 2,087.97 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2008 357 30.1 C 2,482 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2008-12-31
Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 1,654,782.49" (10,000 CNY) = 16,547.82 m x 15% = 2,482.17 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2009 430 20.2 C 2,935 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2009-12-31
Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 1,956,812.38" (10,000 CNY) = 19,568.12 m x 15% = 2,935.22 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2010 663 54.4 C 4,489 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2010-12-31
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 3,741,106.61" (10,000 CNY) = 37,411.07 m x 12% = 4,489.33 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2011 1019 53.7 C 6,588 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2011-12-31
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 5,489,987.25" (10,000 CNY) = 54,899.87 m x 12% = 6,587.98 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2012 1295 27.0 C 8,169 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2012-12-31
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 6,807,811.78" (10,000 CNY) = 68,078.12 m x 12% = 8,169.37 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2013 1527 17.9 C 9,387 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2013-12-31
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 7,822,281.74" (10,000 CNY) = 78,222.82 m x 12% = 9,386.74 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2014 1800 17.9 C 11,088 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2014-12-31
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 9,239,889.36" (10,000 CNY) = 92,398.89 m x 12% = 11,087.87 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2015 2016 12.0 C 12,662 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2015-12-31
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 10,551,658.73" (10,000 CNY) = 105,516.59 m x 12% = 12,661.99 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2016 2183 8.3 C 14,492 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2016-12-31
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 12,076,466.03" (10,000 CNY) = 120,764.66 m x 12% = 14,491.76 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2017 2325 6.5 C 15,702 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2017-12-31
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 13,084,718.19" (10,000 CNY) = 130,847.18 m x 12% = 15,701.66 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
上海医药2018 2891 24.4 C 19,090 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
1590.84亿 total x 12% = 19090.1 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
上海医药2019 2875 -0.6 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shanghai Pharmaceuticals Holding ... 2,875" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
上海医药2020 3340 16.2 C 23,029 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
1919.09亿 total x 12% = 23029.1 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
上海医药2021 4016 20.2 C 25,899 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
2158.24亿 total x 12% = 25898.9 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
上海医药2022 4144 3.2 C 27,838 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
2319.81亿 total x 12% = 27837.7 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
上海医药2023 4415 6.5 C 31,235 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
2602.95亿 total x 12% = 31235.4 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
上海医药2024 4591 4.0 C 33,030 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
2752.51亿 total x 12% = 33030.1 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
上海医药2025 4735 3.1 C 34,030 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
2835.80亿 total x 12% = 34029.6 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
东阿阿胶2000 49 – B 406 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 40,637.05" (10,000 CNY) = 406.37 m
Sina Finance table for stock 000423.
东阿阿胶2001 55 11.4 B 453 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 45,266.70" (10,000 CNY) = 452.67 m
Sina Finance table for stock 000423.
东阿阿胶2002 69 26.1 B 571 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 57,059.66" (10,000 CNY) = 570.60 m
Sina Finance table for stock 000423.
东阿阿胶2003 90 31.2 B 748 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 74,839.77" (10,000 CNY) = 748.40 m
Sina Finance table for stock 000423.
东阿阿胶2004 107 18.0 B 883 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 88,295.38" (10,000 CNY) = 882.95 m
Sina Finance table for stock 000423.
东阿阿胶2005 115 7.6 B 941 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 94,053.82" (10,000 CNY) = 940.54 m
Sina Finance table for stock 000423.
东阿阿胶2006 135 17.2 B 1,073 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 107,291.00" (10,000 CNY) = 1,072.91 m
Sina Finance table for stock 000423.
东阿阿胶2007 182 35.0 B 1,381 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 138,136.07" (10,000 CNY) = 1,381.36 m
Sina Finance table for stock 000423.
东阿阿胶2008 243 33.6 B 1,686 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 168,595.53" (10,000 CNY) = 1,685.96 m
Sina Finance table for stock 000423.
东阿阿胶2009 304 25.4 B 2,079 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 207,910.61" (10,000 CNY) = 2,079.11 m
Sina Finance table for stock 000423.
东阿阿胶2010 364 19.6 B 2,464 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 246,378.43" (10,000 CNY) = 2,463.78 m
Sina Finance table for stock 000423.
东阿阿胶2011 427 17.3 B 2,759 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 275,884.83" (10,000 CNY) = 2,758.85 m
Sina Finance table for stock 000423.
东阿阿胶2012 484 13.5 B 3,056 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 305,607.43" (10,000 CNY) = 3,056.07 m
Sina Finance table for stock 000423.
东阿阿胶2013 653 34.9 B 4,016 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 401,630.44" (10,000 CNY) = 4,016.30 m
Sina Finance table for stock 000423.
东阿阿胶2014 651 -0.4 B 4,009 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 400,901.05" (10,000 CNY) = 4,009.01 m
Sina Finance table for stock 000423.
东阿阿胶2015 868 33.3 B 5,450 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 544,966.32" (10,000 CNY) = 5,449.66 m
Sina Finance table for stock 000423.
东阿阿胶2016 951 9.7 B 6,317 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 631,713.53" (10,000 CNY) = 6,317.14 m
Sina Finance table for stock 000423.
东阿阿胶2017 1092 14.7 B 7,372 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 737,234.03" (10,000 CNY) = 7,372.34 m
Sina Finance table for stock 000423.
东阿阿胶2018 1111 1.8 B 7,338 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 73.38亿元" = 7338 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
东阿阿胶2019 430 -61.3 B 2,970 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 29.70亿元" = 2970 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table; 2019 drop reflects the sharp fall in sales (channel destocking)
东阿阿胶2020 494 14.9 B 3,409 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 34.09亿元" = 3409 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
东阿阿胶2021 597 20.7 B 3,849 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 38.49亿元" = 3849 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
东阿阿胶2022 602 0.8 B 4,042 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 40.42亿元" = 4042 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
东阿阿胶2023 666 10.7 B 4,715 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 47.15亿元" = 4715 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
东阿阿胶2024 856 28.4 B 6,157 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 61.57亿元" = 6157 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
东阿阿胶2025 932 8.9 B 6,700 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 67.00亿元" = 6700 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
中国生物制药2002 44 – B 343 HKD m phx_cn_sino_ar06+fx_fed_h10 Five-year financial summary (read through a search snippet; column order inferred)
Turnover (pharmaceutical)Turnover (pharmaceutical)
same table
Continuing operations only (earlier businesses discontinued); HK$.
中国生物制药2003 59 33.3 B 456 HKD m phx_cn_sino_ar06+fx_fed_h10 Five-year financial summary (read through a search snippet; column order inferred)
Turnover (pharmaceutical)Turnover (pharmaceutical)
same table
Continuing operations only (earlier businesses discontinued); HK$.
中国生物制药2004 85 45.6 B 664 HKD m phx_cn_sino_ar06+fx_fed_h10 Five-year financial summary (read through a search snippet; column order inferred)
Turnover (pharmaceutical)Turnover (pharmaceutical)
same table
Continuing operations only (earlier businesses discontinued); HK$.
中国生物制药2005 97 14.0 B 756 HKD m phx_cn_sino_ar06+fx_fed_h10 Five-year financial summary (read through a search snippet; column order inferred)
Turnover (pharmaceutical)Turnover (pharmaceutical)
same table
Continuing operations only (earlier businesses discontinued); HK$.
中国生物制药2006 95 -2.7 B 735 HKD m phx_cn_sino_ar06+fx_fed_h10 Five-year financial summary (read through a search snippet; column order inferred)
Turnover (pharmaceutical)Turnover (pharmaceutical)
2006 Annual Report five-year summary, continuing operations: 734,652 756,073 664,296 456,089 342,610 (HK$'000; order assumed 2006 to 2002, from the 2005 report chart showing 2003 = 456,089 and 2004 = 664,296)
Continuing operations only (earlier businesses discontinued); HK$.
中国生物制药2007 149 57.8 C 1,164 HKD m phx_sinobio_hkex+fx_fed_h10 2008 results announcement: 2008 turnover +96%
Turnover (pharmaceutical)Turnover (pharmaceutical)
2,282.21 / 1.96 = 1,164.4
Back-calculated from the stated growth of about 96% in 2008; no 2007 figure read directly.
中国生物制药2012 966 – B 7,497 HKD m phx_cn_sino_ar14+fx_fed_h10 Financial Summary (read via pdftotext)
Turnover (pharmaceutical)Turnover (pharmaceutical)
2014 AR Financial Summary: TURNOVER 12,378,350 9,901,196 7,496,888 5,171,354 3,618,773 (HK$'000, 2014 to 2010)
HK$ reporting currency. The same table restates 2010-2011 (3,618.8 and 5,171.4) below the earlier rows (4,086 and 5,782, as first reported) after a disposal; 2012 onward as reported.
中国生物制药2013 1277 32.1 B 9,901 HKD m phx_cn_sino_ar14+fx_fed_h10 Financial Summary (read via pdftotext)
Turnover (pharmaceutical)Turnover (pharmaceutical)
same table: 9,901,196
HK$ reporting currency. The same table restates 2010-2011 (3,618.8 and 5,171.4) below the earlier rows (4,086 and 5,782, as first reported) after a disposal; 2012 onward as reported.
中国生物制药2014 1596 25.1 B 12,378 HKD m phx_cn_sino_ar14+fx_fed_h10 Financial Summary (read via pdftotext)
Turnover (pharmaceutical)Turnover (pharmaceutical)
same table: 12,378,350
HK$ reporting currency. The same table restates 2010-2011 (3,618.8 and 5,171.4) below the earlier rows (4,086 and 5,782, as first reported) after a disposal; 2012 onward as reported.
中国生物制药2015 1877 17.6 B 14,550 HKD m phx_cn_sino_res15+fx_fed_h10 Management discussion, revenue paragraph
Turnover (pharmaceutical)Turnover (pharmaceutical)
The Group recorded revenue of approximately HK$14,550.23 million
HK$ reporting currency.
中国生物制药2016 2039 8.6 B 15,825 HKD m phx_cn_sino_res16+fx_fed_h10 Management discussion, revenue paragraph
Turnover (pharmaceutical)Turnover (pharmaceutical)
The Group recorded revenue of approximately HK$15,825.44 million
Last year in HK$; from FY2017 the group reports in RMB.
中国生物制药2017 2194 7.6 B 14,819 CNY m phx_cn_sino_res17+fx_fed_h10 Financial highlights (b)
Turnover (pharmaceutical)Turnover (pharmaceutical)
revenue of approximately RMB14,819.30 million, +9.4%
RMB from FY2017 (checked in the document); earlier rows are HK$.
中国生物制药2018 3142 43.2 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sino Biopharm ... 3,142" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
中国生物制药2019 3373 7.4 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sino Biopharmaceutical ... 3,373" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
中国生物制药2020 3430 1.7 B 23,647 CNY m phx_cn_sino_res+fx_fed_h10 results / financials table
Turnover (pharmaceutical)Turnover (pharmaceutical)
"Revenue RMB23,647.22 million, -2.4%"
RMB; continuing-operations basis as reported in each year
中国生物制药2021 4165 21.4 B 26,861 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Turnover (pharmaceutical)Turnover (pharmaceutical)
FY2021 26,861
RMB; continuing-operations basis as reported in each year
中国生物制药2022 3875 -7.0 B 26,026 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Turnover (pharmaceutical)Turnover (pharmaceutical)
FY2022 26,026
RMB; continuing-operations basis as reported in each year
中国生物制药2023 3703 -4.4 B 26,199 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Turnover (pharmaceutical)Turnover (pharmaceutical)
FY2023 26,199
RMB; continuing-operations basis as reported in each year
中国生物制药2024 4012 8.3 B 28,866 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Turnover (pharmaceutical)Turnover (pharmaceutical)
FY2024 28,866
RMB; continuing-operations basis as reported in each year
中国生物制药2025 4429 10.4 B 31,834 CNY m phx_cn_sino_res+fx_fed_h10 results / financials table
Turnover (pharmaceutical)Turnover (pharmaceutical)
"Revenue 31.83 bn (2025) vs 28.87 bn (2024), +10.3%"
RMB; continuing-operations basis as reported in each year
中外制药2001 1695 – B 211,700 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 211,700
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
中外制药2003 2010 – B 232,700 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 232,700
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
中外制药2004 2726 35.6 B 294,670 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 294,670
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
中外制药2005 2976 9.2 B 327,155 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 327,155
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
中外制药2006 2803 -5.8 B 326,109 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 326,109
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
中外制药2007 2931 4.5 B 344,808 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 344,808
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
中外制药2008 3171 8.2 B 326,937 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 326,937
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
中外制药2009 4588 44.7 B 428,947 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 428,947
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). 2009 includes the Tamiflu stockpiling boom. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
中外制药2010 4334 -5.6 B 379,509 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 379,509
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
中外制药2011 4690 8.2 B 373,516 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 373,516
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
中外制药2012 4905 4.6 B 391,220 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 391,220
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
中外制药2013 3648 -25.6 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai ... 3,648" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
中外制药2014 3576 -2.0 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai ... 3,576" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
中外制药2015 3297 -7.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai ... 3,297" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
中外制药2016 3699 12.2 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai ... 3,699" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
中外制药2017 3688 -0.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai ... 3,688" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
中外制药2018 3649 -1.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai ... 3,649" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
中外制药2019 3996 9.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai Pharmaceutical ... 3,996" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
中外制药2020 3881 -2.9 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
中外制药2022 1120 – B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
中外制药2023 4036 260.4 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
丽珠集团2000 143 – B 1,182 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 118,205.67" (10,000 CNY) = 1,182.06 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2001 170 19.2 B 1,409 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 140,930.66" (10,000 CNY) = 1,409.31 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2002 195 14.7 B 1,616 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 161,642.92" (10,000 CNY) = 1,616.43 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2003 220 12.4 B 1,818 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 181,765.67" (10,000 CNY) = 1,817.66 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2004 189 -14.2 B 1,560 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 156,030.81" (10,000 CNY) = 1,560.31 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2005 199 5.5 B 1,629 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 162,890.62" (10,000 CNY) = 1,628.91 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2006 190 -4.4 B 1,515 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 151,516.14" (10,000 CNY) = 1,515.16 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2007 230 21.0 B 1,748 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 174,810.84" (10,000 CNY) = 1,748.11 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2008 296 28.9 B 2,059 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 205,864.06" (10,000 CNY) = 2,058.64 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2009 380 28.2 B 2,596 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 259,584.71" (10,000 CNY) = 2,595.85 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2010 403 6.0 B 2,727 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 272,671.89" (10,000 CNY) = 2,726.72 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2011 489 21.5 B 3,163 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 316,291.53" (10,000 CNY) = 3,162.92 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2012 625 27.7 B 3,944 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 394,352.53" (10,000 CNY) = 3,943.53 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2013 751 20.2 B 4,619 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 461,868.00" (10,000 CNY) = 4,618.68 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2014 900 19.8 B 5,544 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 554,423.38" (10,000 CNY) = 5,544.23 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2015 1054 17.1 B 6,621 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 662,051.65" (10,000 CNY) = 6,620.52 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2016 1153 9.4 B 7,652 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 765,177.53" (10,000 CNY) = 7,651.78 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2017 1263 9.6 B 8,531 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 853,096.86" (10,000 CNY) = 8,530.97 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
丽珠集团2018 1342 6.3 B 8,861 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 88.61亿元" = 8861 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
丽珠集团2019 1359 1.3 B 9,385 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 93.85亿元" = 9385 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
丽珠集团2020 1526 12.2 B 10,520 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 105.20亿元" = 10520 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
丽珠集团2021 1871 22.6 B 12,064 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 120.64亿元" = 12064 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
丽珠集团2022 1880 0.5 B 12,630 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 126.30亿元" = 12630 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
丽珠集团2023 1757 -6.6 B 12,430 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 124.30亿元" = 12430 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
丽珠集团2024 1642 -6.6 B 11,812 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 118.12亿元" = 11812 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
丽珠集团2025 1672 1.9 B 12,020 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 120.20亿元" = 12020 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
云南白药2000 96 – B 797 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 79,657.05" (10,000 CNY) = 796.57 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2001 109 13.2 B 901 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 90,144.02" (10,000 CNY) = 901.44 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2002 133 22.2 B 1,101 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 110,119.38" (10,000 CNY) = 1,101.19 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2003 163 22.3 B 1,346 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 134,634.63" (10,000 CNY) = 1,346.35 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2004 222 36.3 B 1,835 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 183,498.86" (10,000 CNY) = 1,834.99 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2005 299 34.9 B 2,451 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 245,083.98" (10,000 CNY) = 2,450.84 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2006 402 34.3 B 3,203 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 320,273.74" (10,000 CNY) = 3,202.74 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2007 541 34.7 B 4,116 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 411,571.69" (10,000 CNY) = 4,115.72 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2008 824 52.2 B 5,723 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 572,319.87" (10,000 CNY) = 5,723.20 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2009 1050 27.4 B 7,172 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 717,178.40" (10,000 CNY) = 7,171.78 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2010 1489 41.8 B 10,075 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 1,007,543.78" (10,000 CNY) = 10,075.44 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2011 1751 17.6 B 11,312 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 1,131,232.24" (10,000 CNY) = 11,312.32 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2012 2170 23.9 B 13,687 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 1,368,682.45" (10,000 CNY) = 13,686.82 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2013 2573 18.6 B 15,815 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 1,581,479.09" (10,000 CNY) = 15,814.79 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2014 3054 18.7 B 18,814 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 1,881,436.64" (10,000 CNY) = 18,814.37 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2015 3301 8.1 B 20,738 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 2,073,812.62" (10,000 CNY) = 20,738.13 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2016 3376 2.3 B 22,411 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 2,241,065.44" (10,000 CNY) = 22,410.65 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2017 3600 6.7 B 24,315 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 2,431,461.40" (10,000 CNY) = 24,314.61 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
云南白药2018 4092 13.7 B 27,017 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 270.17亿元" = 27017 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
云南白药2019 4284 4.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Yunnan Baiyao Group ... 4,284" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
云南白药2020 4749 10.8 B 32,743 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 327.43亿元" = 32743 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
云南白药2021 5640 18.8 B 36,374 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 363.74亿元" = 36374 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
云南白药2022 5432 -3.7 B 36,488 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 364.88亿元" = 36488 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
云南白药2023 5528 1.8 B 39,111 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 391.11亿元" = 39111 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
云南白药2024 5564 0.6 B 40,033 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 400.33亿元" = 40033 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
云南白药2025 5731 3.0 B 41,187 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 411.87亿元" = 41187 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
亚力兄制药2014 2234 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Alexion ... 2,234" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
亚力兄制药2015 2603 16.5 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Alexion ... 2,603" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
亚力兄制药2016 3082 18.4 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Alexion ... 3,082" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
亚力兄制药2017 3550 15.2 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Alexion ... 3,550" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
亚力兄制药2018 4130 16.3 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Alexion ... 4,130" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
亚力兄制药2019 4990 20.8 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Alexion Pharmaceuticals ... 4,990" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
亚力兄制药2020 6069 21.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
亚力兄制药2021 3804 -37.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
优时比2000 1662 – C 1,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2001 1701 2.4 C 1,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2002 1607 -5.5 C 1,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2003 2037 26.8 C 1,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2004 2363 16.0 C 1,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2005 2489 5.3 C 2,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2006 2889 16.0 C 2,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2007 4113 42.4 C 3,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2008 4852 18.0 C 3,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2009 4319 -11.0 C 3,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2010 4116 -4.7 C 3,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2011 4315 4.9 C 3,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2012 4116 -4.6 C 3,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
优时比2013 3802 -7.6 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 3,802" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
优时比2014 3715 -2.3 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 3,715" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
优时比2015 3763 1.3 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 3,763" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
优时比2016 4005 6.4 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 4,005" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
优时比2017 4633 15.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 4,633" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
优时比2018 5138 10.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 5,138" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
优时比2019 5102 -0.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 5,102" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
优时比2020 5455 6.9 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
优时比2021 6395 17.2 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
优时比2022 5663 -11.4 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
优时比2023 5210 -8.0 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
优时比2024 6051 16.1 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
优时比2025 8244 36.2 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
住友制药2005 2000 – C 226,120 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 245,783 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
住友制药2006 2055 2.8 C 240,316 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 261,213 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
住友制药2007 2133 3.8 C 242,873 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 263,992 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
住友制药2008 2427 13.8 C 242,914 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 264,037 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
住友制药2009 2939 21.1 C 272,560 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 296,261 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
住友制药2010 4085 39.0 C 349,152 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 379,513 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
住友制药2011 4085 0.0 C 322,363 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 350,395 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
住友制药2012 3286 -19.6 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon ... 3,286" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
住友制药2014 2944 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon ... 2,944" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
住友制药2015 2902 -1.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon ... 2,902" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
住友制药2016 3197 10.2 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon ... 3,197" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
住友制药2017 3528 10.4 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon ... 3,528" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
住友制药2018 3543 0.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon ... 3,543" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
住友制药2019 3623 2.3 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon Pharma ... 3,623" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
住友制药2020 4028 11.2 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
住友制药2021 4602 14.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
健赞2008 4220 – B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
4100 / (1-2.9%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
健赞2009 4100 -2.8 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
genzyme 4.1 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
健赞2010 4000 -2.4 C phx_est selected data / segment note
Total revenues x ~0.9 (Pharm Exec basis)Total revenues x ~0.9 (Pharm Exec basis)
Genzyme revenue ~4.0-4.5 bn 2009-10; acquired by Sanofi Apr 2011
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
先灵2000 2863 – C 3,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Schering AG total net sales (pharma pure-play, 2006 acqui...Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
先灵2001 3134 9.5 C 3,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Schering AG total net sales (pharma pure-play, 2006 acqui...Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
先灵2002 3876 23.7 C 4,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Schering AG total net sales (pharma pure-play, 2006 acqui...Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
先灵2003 4980 28.5 C 4,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Schering AG total net sales (pharma pure-play, 2006 acqui...Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
先灵2004 5971 19.9 C 4,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Schering AG total net sales (pharma pure-play, 2006 acqui...Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
先灵2005 6597 10.5 C 5,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Schering AG total net sales (pharma pure-play, 2006 acqui...Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
先灵葆雅2000 8500 – C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
先灵葆雅2001 8600 1.2 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
先灵葆雅2002 9100 5.8 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
先灵葆雅2003 7300 -19.8 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
先灵葆雅2004 7300 0.0 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
先灵葆雅2005 8500 16.4 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
先灵葆雅2006 9500 11.8 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
先灵葆雅2007 11000 15.8 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
先灵葆雅2008 13500 22.7 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
兰伯西2008 1678 – B 72,414 INR m phx_rbx_press+fx_fed_h10 results notice
Consolidated net sales (pharma)Consolidated net sales (pharma)
Net Sales Rs 724140.7 lacs for 2008
2008 and 2011 via search snippets only. 2009 restated in AR2010 (73,294 in the earlier release). December year-end.
兰伯西2009 1521 -9.4 A 73,441 INR m phx_rbx_ar2010+fx_fed_h10 Directors report, consolidated sales
Consolidated net sales (pharma)Consolidated net sales (pharma)
Rs. 85,507 millions against Rs.73,441 millions in the previous year
December year-end. The AR2010 ten-year table gives the standalone company only (2001-2010), not used.
兰伯西2010 1874 23.2 A 85,507 INR m phx_rbx_ar2010+fx_fed_h10 Directors report, consolidated sales
Consolidated net sales (pharma)Consolidated net sales (pharma)
consolidated sales of Rs. 85,507 millions
December year-end. The AR2010 ten-year table gives the standalone company only (2001-2010), not used.
兰伯西2011 2147 14.6 B 99,769 INR m phx_rbx_press+fx_fed_h10 results notice
Consolidated net sales (pharma)Consolidated net sales (pharma)
consolidated sales Rs 99,769 Mn
2008 and 2011 via search snippets only. 2009 restated in AR2010 (73,294 in the earlier release). December year-end.
兰伯西2012 2199 2.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ranbaxy ... 2,199" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
再生元2015 2689 – B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Regeneron ... 2,689" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
再生元2016 3338 24.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Regeneron ... 3,338" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
再生元2017 3718 11.4 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Regeneron ... 3,718" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
再生元2018 4106 10.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Regeneron ... 4,106" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
再生元2019 4834 17.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Regeneron ... 4,834" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
再生元2020 5568 15.2 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
再生元2021 12117 117.6 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
再生元2022 6894 -43.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
再生元2023 7078 2.7 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
再生元2024 7629 7.8 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
再生元2025 6309 -17.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
勃林格殷格翰2000 3509 – C 3,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2001 3851 9.7 C 4,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2002 5010 30.1 C 5,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2003 6564 31.0 C 5,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2004 8210 25.1 C 6,600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2005 9335 13.7 C 7,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2006 10425 11.7 C 8,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 8300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2007 12749 22.3 C 9,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 9300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2008 15146 18.8 C 10,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2009 14351 -5.2 C 10,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2010 14205 -1.0 C 10,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2011 15452 8.8 C 11,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2012 15050 -2.6 C 11,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
勃林格殷格翰2013 14468 -3.9 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer Ingelheim ... 14,468" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
勃林格殷格翰2014 13903 -3.9 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer Ingelheim ... 13,903" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
勃林格殷格翰2015 12348 -11.2 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer Ingelheim ... 12,348" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
勃林格殷格翰2016 13316 7.8 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer Ingelheim ... 13,316" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
勃林格殷格翰2017 14262 7.1 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer Ingelheim ... 14,262" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
勃林格殷格翰2018 14834 4.0 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer Ingelheim ... 14,834" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
勃林格殷格翰2019 15629 5.4 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer-Ingelheim ... 15,629" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
勃林格殷格翰2020 16456 5.3 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
勃林格殷格翰2021 17806 8.2 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
勃林格殷格翰2022 19473 9.4 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
勃林格殷格翰2023 20613 5.9 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
勃林格殷格翰2024 22175 7.6 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
勃林格殷格翰2025 23817 7.4 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
华东医药2000 39 – C 324 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2000-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 162,043.08" (10,000 CNY) = 1,620.43 m x 20% = 324.09 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2001 46 16.5 C 377 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2001-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 188,722.05" (10,000 CNY) = 1,887.22 m x 20% = 377.44 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2002 50 10.6 C 418 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2002-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 208,775.74" (10,000 CNY) = 2,087.76 m x 20% = 417.55 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2003 57 12.5 C 470 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2003-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 234,867.82" (10,000 CNY) = 2,348.68 m x 20% = 469.74 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2004 70 23.6 C 581 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2004-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 290,354.18" (10,000 CNY) = 2,903.54 m x 20% = 580.71 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2005 86 22.0 C 701 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2005-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 350,594.62" (10,000 CNY) = 3,505.95 m x 20% = 701.19 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2006 99 16.2 C 793 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2006-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 396,316.38" (10,000 CNY) = 3,963.16 m x 20% = 792.63 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2007 128 28.4 C 971 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2007-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 485,341.34" (10,000 CNY) = 4,853.41 m x 20% = 970.68 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2008 173 35.7 C 1,203 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2008-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 601,648.61" (10,000 CNY) = 6,016.49 m x 20% = 1,203.30 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2009 229 32.2 C 1,565 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2009-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 782,487.22" (10,000 CNY) = 7,824.87 m x 20% = 1,564.97 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2010 265 15.7 C 1,794 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2010-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 897,183.65" (10,000 CNY) = 8,971.84 m x 20% = 1,794.37 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2011 345 29.9 C 2,226 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2011-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 1,113,137.24" (10,000 CNY) = 11,131.37 m x 20% = 2,226.27 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2012 462 34.2 C 2,916 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2012-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 1,457,923.04" (10,000 CNY) = 14,579.23 m x 20% = 2,915.85 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2013 544 17.7 C 3,344 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2013-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 1,671,798.64" (10,000 CNY) = 16,717.99 m x 20% = 3,343.60 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2014 615 13.1 C 3,789 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2014-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 1,894,737.91" (10,000 CNY) = 18,947.38 m x 20% = 3,789.48 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2015 692 12.4 C 4,345 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2015-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 2,172,738.35" (10,000 CNY) = 21,727.38 m x 20% = 4,345.48 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2016 765 10.5 C 5,076 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2016-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 2,537,966.75" (10,000 CNY) = 25,379.67 m x 20% = 5,075.93 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2017 824 7.8 C 5,566 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2017-12-31
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 2,783,182.31" (10,000 CNY) = 27,831.82 m x 20% = 5,566.36 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
华东医药2018 929 12.7 C 6,133 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
306.63亿 total x 20% = 6132.6 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
华东医药2019 1027 10.5 C 7,089 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
354.46亿 total x 20% = 7089.2 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
华东医药2020 977 -4.8 C 6,737 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
336.83亿 total x 20% = 6736.6 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
华东医药2021 1072 9.7 C 6,913 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
345.63亿 total x 20% = 6912.6 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
华东医药2022 1123 4.8 C 7,543 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
377.15亿 total x 20% = 7543.0 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
华东医药2023 1148 2.3 C 8,125 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
406.24亿 total x 20% = 8124.8 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
华东医药2024 1165 1.4 C 8,381 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
419.06亿 total x 20% = 8381.2 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
华东医药2025 1214 4.2 C 8,722 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue
436.12亿 total x 20% = 8722.4 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
华北制药2000 286 – B 2,369 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 236,882.01" (10,000 CNY) = 2,368.82 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2001 348 21.7 B 2,882 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 288,171.11" (10,000 CNY) = 2,881.71 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2002 372 6.7 B 3,076 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 307,610.49" (10,000 CNY) = 3,076.10 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2003 435 17.1 B 3,604 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 360,366.12" (10,000 CNY) = 3,603.66 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2004 502 15.3 B 4,155 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 415,542.72" (10,000 CNY) = 4,155.43 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2005 487 -3.1 B 3,987 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 398,713.91" (10,000 CNY) = 3,987.14 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2006 455 -6.6 B 3,624 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 362,401.93" (10,000 CNY) = 3,624.02 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2007 558 22.7 B 4,241 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 424,058.71" (10,000 CNY) = 4,240.59 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2008 707 26.8 B 4,911 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 491,095.71" (10,000 CNY) = 4,910.96 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2009 715 1.1 B 4,883 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 488,252.21" (10,000 CNY) = 4,882.52 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2010 1520 112.6 B 10,287 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 1,028,664.34" (10,000 CNY) = 10,286.64 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2011 1878 23.6 B 12,137 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 1,213,674.57" (10,000 CNY) = 12,136.75 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2012 1764 -6.1 B 11,126 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 1,112,570.62" (10,000 CNY) = 11,125.71 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2013 2023 14.7 B 12,438 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 1,243,814.37" (10,000 CNY) = 12,438.14 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2014 1526 -24.6 B 9,401 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 940,097.27" (10,000 CNY) = 9,400.97 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2015 1258 -17.6 B 7,902 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 790,250.23" (10,000 CNY) = 7,902.50 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2016 1217 -3.2 B 8,082 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 808,246.28" (10,000 CNY) = 8,082.46 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2017 1141 -6.2 B 7,709 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 770,912.19" (10,000 CNY) = 7,709.12 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
华北制药2018 1396 22.3 B 9,214 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 92.14亿元" = 9214 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华北制药2019 1659 18.9 B 11,457 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 114.57亿元" = 11457 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华北制药2020 1667 0.4 B 11,493 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 114.93亿元" = 11493 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华北制药2021 1610 -3.4 B 10,385 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 103.85亿元" = 10385 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华北制药2022 1563 -2.9 B 10,500 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 105.00亿元" = 10500 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华北制药2023 1430 -8.5 B 10,120 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 101.20亿元" = 10120 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华北制药2024 1372 -4.1 B 9,870 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 98.70亿元" = 9870 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华北制药2025 1286 -6.3 B 9,242 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 92.42亿元" = 9242 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润三九2000 198 – B 1,635 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 163,500.67" (10,000 CNY) = 1,635.01 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2001 226 14.5 B 1,871 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 187,120.28" (10,000 CNY) = 1,871.20 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2002 263 16.1 B 2,173 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 217,318.87" (10,000 CNY) = 2,173.19 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2003 324 23.6 B 2,686 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 268,592.01" (10,000 CNY) = 2,685.92 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2004 300 -7.6 B 2,482 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 248,160.36" (10,000 CNY) = 2,481.60 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2005 366 22.0 B 2,997 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 299,669.16" (10,000 CNY) = 2,996.69 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2006 364 -0.4 B 2,904 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 290,423.25" (10,000 CNY) = 2,904.23 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2007 457 25.5 B 3,478 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 347,756.12" (10,000 CNY) = 3,477.56 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2008 621 35.9 B 4,316 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 431,618.69" (10,000 CNY) = 4,316.19 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2009 710 14.3 B 4,853 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 485,271.70" (10,000 CNY) = 4,852.72 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2010 645 -9.2 B 4,365 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 436,515.33" (10,000 CNY) = 4,365.15 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2011 855 32.6 B 5,525 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 552,522.29" (10,000 CNY) = 5,525.22 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2012 1092 27.8 B 6,891 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 689,110.26" (10,000 CNY) = 6,891.10 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2013 1269 16.2 B 7,802 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 780,160.37" (10,000 CNY) = 7,801.60 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2014 1181 -6.9 B 7,277 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 727,658.56" (10,000 CNY) = 7,276.59 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2015 1258 6.5 B 7,900 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 790,018.96" (10,000 CNY) = 7,900.19 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2016 1353 7.6 B 8,982 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 898,172.11" (10,000 CNY) = 8,981.72 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2017 1646 21.7 B 11,120 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 1,111,991.64" (10,000 CNY) = 11,119.92 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
华润三九2018 2034 23.5 B 13,428 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 134.28亿元" = 13428 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润三九2019 2143 5.4 B 14,794 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 147.94亿元" = 14794 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润三九2020 1978 -7.7 B 13,637 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 136.37亿元" = 13637 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润三九2021 2410 21.9 B 15,544 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 155.44亿元" = 15544 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润三九2022 2691 11.7 B 18,079 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 180.79亿元" = 18079 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润三九2023 3497 29.9 B 24,739 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 247.39亿元" = 24739 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润三九2024 3838 9.8 B 27,617 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 276.17亿元" = 27617 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润三九2025 4397 14.6 B 31,603 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 316.03亿元" = 31603 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润双鹤2000 142 – B 1,175 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 117,533.59" (10,000 CNY) = 1,175.34 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2001 289 103.7 B 2,394 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 239,376.91" (10,000 CNY) = 2,393.77 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2002 448 55.0 B 3,710 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 371,008.74" (10,000 CNY) = 3,710.09 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2003 517 15.4 B 4,280 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 428,000.98" (10,000 CNY) = 4,280.01 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2004 509 -1.6 B 4,210 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 420,974.07" (10,000 CNY) = 4,209.74 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2005 563 10.6 B 4,611 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 461,061.95" (10,000 CNY) = 4,610.62 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2006 510 -9.3 B 4,067 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 406,673.72" (10,000 CNY) = 4,066.74 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2007 599 17.5 B 4,557 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 455,661.64" (10,000 CNY) = 4,556.62 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2008 713 19.0 B 4,952 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 495,152.44" (10,000 CNY) = 4,951.52 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2009 738 3.5 B 5,038 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 503,794.64" (10,000 CNY) = 5,037.95 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2010 793 7.5 B 5,367 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 536,679.58" (10,000 CNY) = 5,366.80 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2011 988 24.6 B 6,383 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 638,337.53" (10,000 CNY) = 6,383.38 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2012 1108 12.2 B 6,989 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 698,932.34" (10,000 CNY) = 6,989.32 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2013 1112 0.3 B 6,835 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 683,457.43" (10,000 CNY) = 6,834.57 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2014 695 -37.5 B 4,281 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 428,096.10" (10,000 CNY) = 4,280.96 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2015 818 17.7 B 5,138 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 513,839.54" (10,000 CNY) = 5,138.40 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2016 828 1.2 B 5,495 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 549,480.39" (10,000 CNY) = 5,494.80 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2017 951 14.9 B 6,422 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 642,184.68" (10,000 CNY) = 6,421.85 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
华润双鹤2018 1246 31.0 B 8,225 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 82.25亿元" = 8225 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润双鹤2019 1359 9.1 B 9,381 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 93.81亿元" = 9381 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润双鹤2020 1233 -9.2 B 8,504 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 85.04亿元" = 8504 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润双鹤2021 1413 14.5 B 9,112 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 91.12亿元" = 9112 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润双鹤2022 1433 1.4 B 9,625 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 96.25亿元" = 9625 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润双鹤2023 1599 11.6 B 11,310 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 113.10亿元" = 11310 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润双鹤2024 1558 -2.5 B 11,212 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 112.12亿元" = 11212 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
华润双鹤2025 1531 -1.8 B 11,001 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 110.01亿元" = 11001 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
协和麒麟2010 3165 – C 277,204 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Pharmaceutical revenue estimate = group net sales x 0.67Pharmaceutical revenue estimate = group net sales x 0.67
group net sales 413,738 x 0.67
Share 0.67 calibrated to the Pharm Exec 2014 row for 2013 (2,334 US$ m x 97.6 = 228 bn / 341 bn); the group includes Kyowa Hakko Bio and chemicals. Kyowa Hakko Kirin formed Oct 2008; the 9-month transition period 2009 is left out. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
协和麒麟2011 2892 -8.6 C 230,294 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Pharmaceutical revenue estimate = group net sales x 0.67Pharmaceutical revenue estimate = group net sales x 0.67
group net sales 343,722 x 0.67
Share 0.67 calibrated to the Pharm Exec 2014 row for 2013 (2,334 US$ m x 97.6 = 228 bn / 341 bn); the group includes Kyowa Hakko Bio and chemicals. Kyowa Hakko Kirin formed Oct 2008; the 9-month transition period 2009 is left out. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
协和麒麟2012 2798 -3.2 C 223,216 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Pharmaceutical revenue estimate = group net sales x 0.67Pharmaceutical revenue estimate = group net sales x 0.67
group net sales 333,158 x 0.67
Share 0.67 calibrated to the Pharm Exec 2014 row for 2013 (2,334 US$ m x 97.6 = 228 bn / 341 bn); the group includes Kyowa Hakko Bio and chemicals. Kyowa Hakko Kirin formed Oct 2008; the 9-month transition period 2009 is left out. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
协和麒麟2013 2334 -16.6 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Kyowa Hakko Kirin ... 2,334" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
协和麒麟2014 2157 -7.6 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Kyowa Hakko Kirin ... 2,157" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
协和麒麟2016 2228 – B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Kyowa Hakko Kirin ... 2,228" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
协和麒麟2017 2272 2.0 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Kyowa Hakko Kirin ... 2,272" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
协和麒麟2021 2959 – B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
博士康2013 4196 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Valeant ... 4,196" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
博士康2014 5007 19.3 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Valeant ... 5,007" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
博士康2015 7013 40.1 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Valeant ... 7,013" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
博士康2016 6183 -11.8 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Valeant ... 6,183" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
博士康2017 5053 -18.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Valeant ... 5,053" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
博士康2018 4631 -8.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bausch Health ... 4,631" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
博士康2019 5295 14.3 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bausch Health Companies ... 5,295" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
博士康2020 4884 -7.8 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
博士康2021 4924 0.8 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
博士康2022 6569 33.4 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
博士康2023 4418 -32.7 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
博士康2024 4977 12.7 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
博士康2025 5406 8.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
卫材2000 2719 – C 300,211 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 361,700 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
卫材2001 2868 5.5 C 358,289 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 431,673 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
卫材2002 3180 10.9 C 387,278 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 466,600 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
卫材2003 3682 15.8 C 415,083 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 500,100 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
卫材2004 4118 11.9 C 442,390 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 533,000 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
卫材2005 4414 7.2 C 499,039 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 601,252 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
卫材2006 4785 8.4 C 559,512 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 674,111 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
卫材2007 5353 11.9 C 609,457 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 734,286 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
卫材2008 6484 21.1 C 648,847 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 781,743 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
卫材2009 7187 10.8 C 666,616 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 803,152 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
卫材2010 7467 3.9 C 638,199 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 768,914 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
卫材2011 6816 -8.7 C 537,820 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 647,976 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
卫材2012 4821 -29.3 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 4,821" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
卫材2014 4422 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 4,422" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
卫材2015 3909 -11.6 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 3,909" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
卫材2016 4301 10.0 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 4,301" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
卫材2017 4359 1.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 4,359" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
卫材2018 4531 3.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 4,531" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
卫材2019 4703 3.8 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 4,703" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
卫材2020 5107 8.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
卫材2021 5224 2.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
卫材2022 4596 -12.0 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
卫材2023 4305 -6.3 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
卫材2024 4536 5.4 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
卫材2025 4775 5.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
史达德2000 554 – C 600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2001 627 13.1 C 700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2002 756 20.6 C 800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2003 1019 34.7 C 900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2004 1244 22.1 C 1,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2005 1369 10.1 C 1,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2006 1633 19.3 C 1,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2007 1919 17.5 C 1,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2008 2206 14.9 C 1,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2009 2369 7.4 C 1,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2010 2522 6.5 C 1,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2011 2645 4.9 C 1,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2012 2701 2.1 C 2,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
史达德2013 2407 -10.9 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"STADA ... 2,407" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
史达德2014 2405 -0.1 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"STADA ... 2,405" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
史达德2017 2348 – B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"STADA ... 2,348" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
史达德2018 2467 5.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"STADA ... 2,467" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
史达德2020 2823 – B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
史达德2021 3097 9.7 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
史达德2023 3896 – B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
史达德2024 3930 0.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
史达德2025 4017 2.2 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
吉利德科学2002 466 – C phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
吉利德科学2004 1325 – B phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
吉利德科学2005 2028 53.1 B phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
吉利德科学2006 3026 49.2 B phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
吉利德科学2007 4230 39.8 B phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
吉利德科学2008 5130 21.3 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
6500 / (1+26.8%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
吉利德科学2009 6500 26.7 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
gilead 6.5 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
吉利德科学2010 7949 22.3 B phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
吉利德科学2011 8100 1.9 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
gilead $8.1 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
吉利德科学2012 9702 19.8 B phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
吉利德科学2013 10804 11.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Sciences ... 10,804" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
吉利德科学2014 24474 126.5 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Sciences ... 24,474" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
吉利德科学2015 32151 31.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Sciences ... 32,151" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
吉利德科学2016 29992 -6.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Sciences ... 29,992" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
吉利德科学2017 25662 -14.4 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Sciences ... 25,662" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
吉利德科学2018 21677 -15.5 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Sciences ... 21,677" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
吉利德科学2019 21703 0.1 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Science ... 21,703" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
吉利德科学2020 23806 9.7 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
吉利德科学2021 27005 13.4 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
吉利德科学2022 26615 -1.4 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
吉利德科学2023 26461 -0.6 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
吉利德科学2024 28028 5.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
吉利德科学2025 28828 2.9 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
同仁堂2000 124 – B 1,025 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 102,513.17" (10,000 CNY) = 1,025.13 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2001 195 57.3 B 1,612 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 161,250.39" (10,000 CNY) = 1,612.50 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2002 241 23.6 B 1,993 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 199,296.29" (10,000 CNY) = 1,992.96 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2003 263 9.1 B 2,174 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 217,364.96" (10,000 CNY) = 2,173.65 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2004 297 13.0 B 2,457 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 245,674.09" (10,000 CNY) = 2,456.74 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2005 319 7.5 B 2,614 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 261,355.38" (10,000 CNY) = 2,613.55 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2006 302 -5.3 B 2,408 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 240,781.26" (10,000 CNY) = 2,407.81 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2007 355 17.7 B 2,703 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 270,285.09" (10,000 CNY) = 2,702.85 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2008 423 19.0 B 2,939 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 293,904.95" (10,000 CNY) = 2,939.05 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2009 476 12.4 B 3,250 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 325,021.99" (10,000 CNY) = 3,250.22 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2010 565 18.8 B 3,824 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 382,444.61" (10,000 CNY) = 3,824.45 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2011 945 67.3 B 6,108 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 610,838.37" (10,000 CNY) = 6,108.38 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2012 1190 25.8 B 7,504 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 750,403.20" (10,000 CNY) = 7,504.03 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2013 1418 19.2 B 8,715 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 871,464.74" (10,000 CNY) = 8,714.65 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2014 1572 10.9 B 9,686 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 968,586.75" (10,000 CNY) = 9,685.87 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2015 1721 9.4 B 10,809 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 1,080,876.12" (10,000 CNY) = 10,808.76 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2016 1821 5.8 B 12,091 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 1,209,074.01" (10,000 CNY) = 12,090.74 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2017 1980 8.7 B 13,376 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 1,337,596.63" (10,000 CNY) = 13,375.97 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
同仁堂2018 2152 8.7 B 14,209 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 142.09亿元" = 14209 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
同仁堂2019 1923 -10.6 B 13,277 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 132.77亿元" = 13277 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
同仁堂2020 1860 -3.3 B 12,826 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 128.26亿元" = 12826 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
同仁堂2021 2264 21.7 B 14,603 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 146.03亿元" = 14603 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
同仁堂2022 2288 1.1 B 15,372 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 153.72亿元" = 15372 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
同仁堂2023 2525 10.3 B 17,861 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 178.61亿元" = 17861 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
同仁堂2024 2585 2.4 B 18,597 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 185.97亿元" = 18597 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
同仁堂2025 2401 -7.1 B 17,256 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 172.56亿元" = 17256 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
哈药集团2000 780 – B 6,455 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 645,531.53" (10,000 CNY) = 6,455.32 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2001 649 -16.8 B 5,370 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 537,001.85" (10,000 CNY) = 5,370.02 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2002 787 21.4 B 6,518 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 651,750.26" (10,000 CNY) = 6,517.50 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2003 838 6.4 B 6,936 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 693,616.66" (10,000 CNY) = 6,936.17 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2004 869 3.7 B 7,191 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 719,118.43" (10,000 CNY) = 7,191.18 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2005 1039 19.6 B 8,510 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 851,036.24" (10,000 CNY) = 8,510.36 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2006 1158 11.4 B 9,228 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 922,817.96" (10,000 CNY) = 9,228.18 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2007 1090 -5.8 B 8,290 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 829,026.99" (10,000 CNY) = 8,290.27 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2008 1396 28.0 B 9,695 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 969,506.81" (10,000 CNY) = 9,695.07 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2009 1563 12.0 B 10,677 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,067,730.06" (10,000 CNY) = 10,677.30 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2010 1852 18.5 B 12,535 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,253,543.98" (10,000 CNY) = 12,535.44 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2011 2087 12.7 B 13,487 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,348,696.04" (10,000 CNY) = 13,486.96 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2012 2800 34.2 B 17,663 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,766,294.69" (10,000 CNY) = 17,662.95 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2013 2943 5.1 B 18,092 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,809,193.45" (10,000 CNY) = 18,091.93 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2014 2680 -8.9 B 16,509 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,650,891.25" (10,000 CNY) = 16,508.91 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2015 2524 -5.8 B 15,856 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,585,620.78" (10,000 CNY) = 15,856.21 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2016 2128 -15.7 B 14,127 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,412,688.60" (10,000 CNY) = 14,126.89 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2017 1779 -16.4 B 12,018 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,201,753.13" (10,000 CNY) = 12,017.53 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
哈药集团2018 1638 -7.9 B 10,814 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 108.14亿元" = 10814 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
哈药集团2019 1713 4.6 B 11,825 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 118.25亿元" = 11825 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
哈药集团2020 1565 -8.7 B 10,788 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 107.88亿元" = 10788 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
哈药集团2021 1985 26.9 B 12,802 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 128.02亿元" = 12802 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
哈药集团2022 2056 3.6 B 13,809 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 138.09亿元" = 13809 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
哈药集团2023 2185 6.3 B 15,457 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 154.57亿元" = 15457 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
哈药集团2024 2248 2.9 B 16,176 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 161.76亿元" = 16176 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
哈药集团2025 2221 -1.2 B 15,964 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 159.64亿元" = 15964 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
因塞特2022 3747 – B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
因塞特2023 3165 -15.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
因塞特2024 3619 14.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
因塞特2025 4354 20.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
基因泰克2004 4621 – B phx_est selected data / segment note
Total operating revenues (product sales + royalties + con...Total operating revenues (product sales + royalties + contract)
Genentech total operating revenues; acquired by Roche Mar 2009
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
基因泰克2005 6633 43.5 B phx_est selected data / segment note
Total operating revenues (product sales + royalties + con...Total operating revenues (product sales + royalties + contract)
Genentech total operating revenues; acquired by Roche Mar 2009
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
基因泰克2006 9284 40.0 B phx_est selected data / segment note
Total operating revenues (product sales + royalties + con...Total operating revenues (product sales + royalties + contract)
Genentech total operating revenues; acquired by Roche Mar 2009
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
基因泰克2007 11724 26.3 B phx_est selected data / segment note
Total operating revenues (product sales + royalties + con...Total operating revenues (product sales + royalties + contract)
Genentech total operating revenues; acquired by Roche Mar 2009
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
基因泰克2008 13418 14.4 B phx_est selected data / segment note
Total operating revenues (product sales + royalties + con...Total operating revenues (product sales + royalties + contract)
Genentech total operating revenues; acquired by Roche Mar 2009
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
基立福2000 185 – C 200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2001 224 21.2 C 250 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 250 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2002 378 68.9 C 400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2003 566 49.6 C 500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2004 746 31.9 C 600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2005 871 16.7 C 700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2006 1005 15.3 C 800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2007 1234 22.8 C 900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2008 1470 19.2 C 1,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2009 1533 4.2 C 1,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2010 1726 12.6 C 1,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2011 3898 125.8 C 2,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2012 3988 2.3 C 3,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
基立福2013 3245 -18.6 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 3,245" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
基立福2014 3255 0.3 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 3,255" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
基立福2015 3365 3.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 3,365" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
基立福2016 3572 6.2 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 3,572" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
基立福2017 3876 8.5 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 3,876" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
基立福2018 4154 7.2 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 4,154" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
基立福2019 4471 7.6 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 4,471" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
基立福2021 4516 – B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
基立福2022 4864 7.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
基立福2023 6012 23.6 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
基立福2024 6646 10.5 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
基立福2025 7332 10.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
复星医药2000 42 – C 346 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2000-12-31
Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenue
total 576.14 m x 60% = 345.68 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
复星医药2001 53 27.0 C 439 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2001-12-31
Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenue
total 731.59 m x 60% = 438.95 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
复星医药2002 76 42.6 C 626 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2002-12-31
Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenue
total 1,043.19 m x 60% = 625.92 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
复星医药2003 158 108.9 C 1,307 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2003-12-31
Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenue
total 2,178.79 m x 60% = 1,307.27 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
复星医药2004 179 13.1 C 1,478 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2004-12-31
Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenue
total 2,463.52 m x 60% = 1,478.11 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
复星医药2005 223 25.1 C 1,830 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2005-12-31
Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenue
total 3,050.15 m x 60% = 1,830.09 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
复星医药2006 239 6.8 C 1,901 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2006-12-31
Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenue
total 3,168.68 m x 60% = 1,901.21 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
复星医药2007 291 22.2 C 2,216 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2007-12-31
Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenue
total 3,693.30 m x 60% = 2,215.98 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
复星医药2008 326 11.8 C 2,264 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2008-12-31
Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenue
total 3,773.23 m x 60% = 2,263.94 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
复星医药2009 333 2.2 B 2,275 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
2,812 / 1.2361 (2010 segment 2,812, +23.61%)
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
复星医药2010 415 24.7 B 2,812 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
2010 pharmaceutical manufacturing segment revenue RMB 2.812 bn, +23.61%
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
复星医药2011 622 49.8 C 4,021 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2011-12-31
Pharmaceutical manufacturing estimated as 62% of total re...Pharmaceutical manufacturing estimated as 62% of total revenue
total 6,485.54 m x 62% = 4,021.04 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
复星医药2012 734 18.0 B 4,633 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
6,524 / 1.4082 (2013 segment 6,524, +40.82% on 2012)
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
复星医药2013 1061 44.5 B 6,524 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
Pharmaceutical manufacturing and R&D segment revenue RMB 6,524 m, +40.82%
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
复星医药2014 1191 12.2 B 7,338 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
R&D RMB 452 m = 6.16% of segment revenue -> 452/0.0616 = 7,338
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
复星医药2015 1408 18.2 B 8,843 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
Segment revenue 8,843 (comparative in 2017 annual results)
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
复星医药2016 1529 8.6 B 10,150 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
Segment revenue 10,150, +14.78%
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
复星医药2017 1931 26.3 B 13,043 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
Segment revenue 13,043 (2017 annual results; a Fosun release gives 13,195.47)
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
复星医药2018 2785 44.2 C 18,390 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing and R&D segment revenue (est...Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)
group 249.18亿 x 73.80% = 18389 RMB m
Share interpolated between the reported 2017/2019 and 2022/2023 shares (about 68-76%); segment table not retrieved
复星医药2019 3157 13.3 B 21,796 CNY m phx_cn_10jqka+phx_cn_fosun_rep+fx_fed... annual table, row 营业总收入
Pharmaceutical manufacturing and R&D segment revenue (est...Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)
group 285.85亿 x 76.25% = 21796 RMB m
Broker note quotes pharma share 76.25% in 2019 (71.33% in 2017); segment table not retrieved
复星医药2020 3341 5.8 C 23,033 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing and R&D segment revenue (est...Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)
group 303.07亿 x 76.00% = 23033 RMB m
Share interpolated between the reported 2017/2019 and 2022/2023 shares (about 68-76%); segment table not retrieved
复星医药2021 4113 23.1 C 26,528 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing and R&D segment revenue (est...Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)
group 390.11亿 x 68.00% = 26527 RMB m
Share interpolated between the reported 2017/2019 and 2022/2023 shares (about 68-76%); segment table not retrieved
复星医药2022 4587 11.5 B 30,810 CNY m phx_cn_fosun_rep+fx_fed_h10 article text
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
2023 pharma 302.22亿, -1.91% yoy => 2022 = 302.22/0.9809 = 30,811
Backed out from the reported 2023 figure and its growth rate
复星医药2023 4272 -6.9 B 30,222 CNY m phx_cn_fosun_rep+fx_fed_h10 article text
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
"制药板块 302.22亿元, -1.91%"
Article reprint of the annual report
复星医药2024 4109 -3.8 C 29,568 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing and R&D segment revenue (est...Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)
group 410.67亿 x 72% = 29,568 RMB m
Share of about 72% bracketed by 73.0% (2023) and 71.6% (2025); segment table not retrieved
复星医药2025 4151 1.0 B 29,834 CNY m phx_cn_fosun_ann25+fx_fed_h10 results summary
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
innovative drug revenue RMB 9.893 bn = 33.16% of pharmaceutical business revenue => 29,834
Derived from two reported figures (innovative drugs and their share)
夏尔2000 500 – C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2001 600 20.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 600 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2002 800 33.3 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 800 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2003 1000 25.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2004 1300 30.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2005 1500 15.4 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2006 1700 13.3 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2007 1800 5.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2008 2000 11.1 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2009 2400 20.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2010 2700 12.5 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2700 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2011 3500 29.6 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2012 4700 34.3 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4700 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
夏尔2013 4847 3.1 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shire ... 4,847" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
夏尔2014 5830 20.3 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shire ... 5,830" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
夏尔2015 6100 4.6 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shire ... 6,100" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
夏尔2016 10886 78.5 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shire ... 10,886" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
夏尔2017 14449 32.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shire ... 14,449" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
夏尔2018 14993 3.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shire ... 14,993" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
大冢2002 2686 – C 327,129 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 474,100 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大冢2003 2991 11.4 C 337,203 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 488,700 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大冢2004 4392 46.8 C 471,822 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 683,800 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大冢2005 4596 4.6 C 519,639 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 753,100 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大冢2006 5039 9.6 C 589,191 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 853,900 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大冢2007 5627 11.7 C 640,596 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 928,400 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大冢2008 6591 17.1 C 659,571 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 955,900 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大冢2009 8066 22.4 C 748,161 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 1,084,291 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大冢2010 9103 12.9 C 778,036 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 1,127,589 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大冢2011 10096 10.9 C 796,655 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 1,154,573 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大冢2012 8655 -14.3 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka ... 8,655" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
大冢2014 6961 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka ... 6,961" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
大冢2015 6728 -3.3 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka ... 6,728" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
大冢2016 5389 -19.9 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka ... 5,389" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
大冢2017 5324 -1.2 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka ... 5,324" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
大冢2018 5726 7.6 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka ... 5,726" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
大冢2019 6711 17.2 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka Holdings ... 6,711" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
大冢2020 7219 7.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
大冢2021 7368 2.1 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
大冢2022 7357 -0.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
大冢2023 7970 8.3 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
大冢2024 8975 12.6 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
大冢2025 9869 10.0 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
大日本制药2000 1223 – C 135,065 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.85
group net sales 158,900 x 0.85
Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大日本制药2001 1117 -8.7 C 139,499 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.85
group net sales 164,117 x 0.85
Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大日本制药2002 1202 7.6 C 146,337 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.85
group net sales 172,161 x 0.85
Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大日本制药2003 1288 7.2 C 145,216 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.85
group net sales 170,842 x 0.85
Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
大日本制药2004 1376 6.8 C 147,814 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.85
group net sales 173,899 x 0.85
Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
天士力2000 47 – B 392 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 39,158.28" (10,000 CNY) = 391.58 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2001 83 74.9 B 685 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 68,456.88" (10,000 CNY) = 684.57 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2002 112 35.8 B 930 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 92,979.17" (10,000 CNY) = 929.79 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2003 128 13.6 B 1,056 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 105,580.53" (10,000 CNY) = 1,055.81 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2004 157 23.3 B 1,302 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 130,177.76" (10,000 CNY) = 1,301.78 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2005 179 13.8 B 1,466 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 146,608.38" (10,000 CNY) = 1,466.08 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2006 303 69.5 B 2,417 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 241,708.70" (10,000 CNY) = 2,417.09 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2007 368 21.2 B 2,795 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 279,490.58" (10,000 CNY) = 2,794.91 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2008 494 34.5 B 3,434 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 343,421.55" (10,000 CNY) = 3,434.22 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2009 585 18.2 B 3,993 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 399,264.53" (10,000 CNY) = 3,992.65 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2010 687 17.6 B 4,652 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 465,159.11" (10,000 CNY) = 4,651.59 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2011 1017 47.9 B 6,570 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 656,966.46" (10,000 CNY) = 6,569.66 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2012 1475 45.0 B 9,301 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 930,145.58" (10,000 CNY) = 9,301.46 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2013 1807 22.5 B 11,108 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 1,110,806.59" (10,000 CNY) = 11,108.07 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2014 2042 13.0 B 12,578 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 1,257,770.15" (10,000 CNY) = 12,577.70 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2015 2106 3.1 B 13,228 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 1,322,751.22" (10,000 CNY) = 13,227.51 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2016 2100 -0.2 B 13,946 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 1,394,549.70" (10,000 CNY) = 13,945.50 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2017 2383 13.4 B 16,094 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 1,609,415.00" (10,000 CNY) = 16,094.15 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
天士力2018 2725 14.3 B 17,990 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 179.90亿元" = 17990 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
天士力2019 2752 1.0 B 18,998 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 189.98亿元" = 18998 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
天士力2020 1969 -28.4 B 13,576 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 135.76亿元" = 13576 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
天士力2021 1233 -37.4 B 7,952 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 79.52亿元" = 7952 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
天士力2022 1286 4.3 B 8,637 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 86.37亿元" = 8637 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
天士力2023 1226 -4.7 B 8,674 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 86.74亿元" = 8674 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
天士力2024 1181 -3.7 B 8,498 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 84.98亿元" = 8498 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
天士力2025 1146 -3.0 B 8,236 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 82.36亿元" = 8236 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
太阳制药2001 157 – B 7,505 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 7,505 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
太阳制药2002 201 27.7 B 9,725 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 9,725 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
太阳制药2003 214 6.7 B 9,847 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 9,847 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
太阳制药2004 267 24.7 B 11,983 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 11,983 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
太阳制药2005 393 47.2 B 17,372 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 17,372 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
太阳制药2006 496 26.1 B 22,373 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 22,373 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
太阳制药2007 863 73.9 B 34,606 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 34,606 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
太阳制药2008 959 11.1 B 43,751 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 43,751 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
太阳制药2009 805 -16.1 B 38,086 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 38,086 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
太阳制药2010 1258 56.3 B 57,214 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 57,214 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
太阳制药2012 2311 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma ... 2,311" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
太阳制药2014 5012 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma ... 5,012" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
太阳制药2015 4503 -10.2 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma ... 4,503" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
太阳制药2016 4804 6.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma ... 4,804" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
太阳制药2017 4147 -13.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma ... 4,147" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
太阳制药2018 4222 1.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma ... 4,222" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
太阳制药2019 4658 10.3 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma Industries ... 4,658" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
太阳制药2020 4630 -0.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
太阳制药2021 5091 10.0 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
太阳制药2022 5424 6.5 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
太阳制药2023 5789 6.7 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
太阳制药2024 6081 5.0 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
太阳制药2025 6441 5.9 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
安万特2000 12281 – C 13,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur v...Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur vaccines; Aventis CropScience and Behring excluded)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 13300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
安万特2001 12985 5.7 C 14,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur v...Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur vaccines; Aventis CropScience and Behring excluded)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 14500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
安万特2002 15881 22.3 C 16,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur v...Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur vaccines; Aventis CropScience and Behring excluded)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 16800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
安斯泰来2005 7777 – B 879,361 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 879,361
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
安斯泰来2006 7873 1.2 B 920,624 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 920,624
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
安斯泰来2007 8543 8.5 B 972,586 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 972,586
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
安斯泰来2008 9650 13.0 B 965,698 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 965,698
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
安斯泰来2009 10511 8.9 B 974,877 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 974,877
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
安斯泰来2010 11161 6.2 B 953,947 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 953,947
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
安斯泰来2011 12285 10.1 B 969,387 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 969,387
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
安斯泰来2012 10431 -15.1 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas ... 10,431" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
安斯泰来2014 10419 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas ... 10,419" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
安斯泰来2015 10937 5.0 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas ... 10,937" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
安斯泰来2016 11109 1.6 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas ... 11,109" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
安斯泰来2017 10888 -2.0 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas ... 10,888" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
安斯泰来2018 11036 1.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas ... 11,036" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
安斯泰来2019 11444 3.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas Pharma ... 11,444" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
安斯泰来2020 11515 0.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
安斯泰来2021 11828 2.7 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
安斯泰来2022 10511 -11.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
安斯泰来2023 10377 -1.3 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
安斯泰来2024 11816 13.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
安斯泰来2025 12597 6.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
安进2000 3629 – B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
安进2001 4016 10.7 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
安进2002 5523 37.5 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
安进2003 8356 51.3 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
安进2004 10550 26.3 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
安进2005 12430 17.8 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
安进2006 14268 14.8 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
安进2007 14771 3.5 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
安进2008 14750 -0.1 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
14400 / (1-2.4%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
安进2009 14400 -2.4 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
amgen 14.4 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
安进2010 15053 4.5 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
安进2011 15300 1.6 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
amgen $15.3 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
安进2012 17265 12.8 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
安进2013 18192 5.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 18,192" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
安进2014 19327 6.2 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 19,327" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
安进2015 20944 8.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 20,944" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
安进2016 21892 4.5 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 21,892" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
安进2017 21795 -0.4 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 21,795" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
安进2018 22533 3.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 22,533" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
安进2019 22204 -1.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 22,204" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
安进2020 24098 8.5 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
安进2021 23957 -0.6 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
安进2022 22536 -5.9 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
安进2023 26621 18.1 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
安进2024 31748 19.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
安进2025 34950 10.1 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
小野制药2001 1046 – C 130,686 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 133,353 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
小野制药2002 1086 3.8 C 132,293 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 134,993 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
小野制药2003 1212 11.5 C 136,595 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 139,383 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
小野制药2004 1326 9.4 C 142,396 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 145,302 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
小野制药2005 1289 -2.8 C 145,698 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 148,671 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
小野制药2006 1188 -7.8 C 138,877 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 141,711 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
小野制药2007 1256 5.7 C 142,979 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 145,897 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
小野制药2008 1337 6.5 C 133,825 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 136,556 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
小野制药2009 1437 7.4 C 133,266 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 135,986 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
小野制药2010 1551 7.9 C 132,550 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 135,255 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
小野制药2011 1810 16.7 C 142,862 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 145,778 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
小野制药2016 2153 – B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ono ... 2,153" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
小野制药2017 2363 9.8 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ono ... 2,363" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
小野制药2019 3266 – B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ono Pharmaceutical ... 3,266" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
小野制药2020 2908 -11.0 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
山之内制药2001 3853 – B 481,300 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (Yamanouchi, practically all pharma)Consolidated net sales (Yamanouchi, practically all pharma)
consolidated net sales 481,300
Pre-merger values of the page for code 4503 (Yamanouchi Pharmaceutical; the page does not name the entity, inferred from the 2005 merger). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
山之内制药2002 4160 8.0 B 506,600 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (Yamanouchi, practically all pharma)Consolidated net sales (Yamanouchi, practically all pharma)
consolidated net sales 506,600
Pre-merger values of the page for code 4503 (Yamanouchi Pharmaceutical; the page does not name the entity, inferred from the 2005 merger). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
山之内制药2003 4535 9.0 B 511,200 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (Yamanouchi, practically all pharma)Consolidated net sales (Yamanouchi, practically all pharma)
consolidated net sales 511,200
Pre-merger values of the page for code 4503 (Yamanouchi Pharmaceutical; the page does not name the entity, inferred from the 2005 merger). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
山之内制药2004 4162 -8.2 B 447,100 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (Yamanouchi, practically all pharma)Consolidated net sales (Yamanouchi, practically all pharma)
consolidated net sales 447,100
Pre-merger values of the page for code 4503 (Yamanouchi Pharmaceutical; the page does not name the entity, inferred from the 2005 merger). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
山德士2023 9647 – B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
山德士2024 10357 7.4 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
山德士2025 11086 7.0 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
强生2000 9500 – C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
强生2001 11100 16.8 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
强生2002 13100 18.0 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
强生2003 15300 16.8 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
强生2004 17500 14.4 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
强生2005 20300 16.0 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
强生2006 23300 14.8 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
强生2007 24600 5.6 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
强生2008 24590 0.0 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
22500 / (1-8.5%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
强生2009 22500 -8.5 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
jnj 22.5 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
强生2010 22400 -0.4 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
强生2011 24400 8.9 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
jnj $24.4 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
强生2012 25400 4.1 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
强生2013 26475 4.2 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson & Johnson ... 26,475" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
强生2014 30726 16.1 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson & Johnson ... 30,726" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
强生2015 29864 -2.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson & Johnson ... 29,864" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
强生2016 31671 6.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson & Johnson ... 31,671" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
强生2017 34397 8.6 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson & Johnson ... 34,397" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
强生2018 38815 12.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson & Johnson ... 38,815" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
强生2019 40083 3.3 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson &Johnson ... 40,083" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
强生2020 43149 7.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
强生2021 49821 15.5 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
强生2022 50179 0.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
强生2023 53463 6.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
强生2024 55745 4.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
强生2025 59331 6.4 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
恒瑞医药2000 59 – B 489 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 48,876.18" (10,000 CNY) = 488.76 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2001 77 30.5 B 638 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 63,752.23" (10,000 CNY) = 637.52 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2002 92 18.9 B 758 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 75,823.71" (10,000 CNY) = 758.24 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2003 127 39.0 B 1,054 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 105,433.96" (10,000 CNY) = 1,054.34 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2004 139 9.0 B 1,149 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 114,886.91" (10,000 CNY) = 1,148.87 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2005 145 4.7 B 1,191 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 119,057.55" (10,000 CNY) = 1,190.58 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2006 179 22.9 B 1,423 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 142,345.61" (10,000 CNY) = 1,423.46 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2007 258 44.3 B 1,960 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 195,966.01" (10,000 CNY) = 1,959.66 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2008 344 33.7 B 2,393 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 239,256.12" (10,000 CNY) = 2,392.56 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2009 443 28.7 B 3,029 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 302,896.09" (10,000 CNY) = 3,028.96 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2010 553 24.7 B 3,744 CNY m phx_hengrui_notes+fx_fed_h10 broker commentary on the annual report
Total revenue (pharma)Total revenue (pharma)
2010A revenue 3,744.11 m
Figures from broker notes surfaced by search (Eastmoney PDFs); the annual reports on sse.com.cn not opened.
恒瑞医药2011 704 27.3 B 4,550 CNY m phx_hengrui_notes+fx_fed_h10 broker commentary on the annual report
Total revenue (pharma)Total revenue (pharma)
2011 revenue 4.550 bn, +21.53%
Figures from broker notes surfaced by search (Eastmoney PDFs); the annual reports on sse.com.cn not opened.
恒瑞医药2012 862 22.4 B 5,435 CNY m phx_hengrui_notes+fx_fed_h10 broker commentary on the annual report
Total revenue (pharma)Total revenue (pharma)
2012 revenue 5.435 bn, +19.44%
Figures from broker notes surfaced by search (Eastmoney PDFs); the annual reports on sse.com.cn not opened.
恒瑞医药2013 1009 17.1 B 6,203 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 620,307.44" (10,000 CNY) = 6,203.07 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2014 1210 19.9 B 7,452 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 745,225.31" (10,000 CNY) = 7,452.25 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2015 1483 22.6 B 9,316 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 931,596.02" (10,000 CNY) = 9,315.96 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2016 1671 12.7 B 11,094 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 1,109,372.41" (10,000 CNY) = 11,093.72 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2017 2049 22.6 B 13,836 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 1,383,562.94" (10,000 CNY) = 13,835.63 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
恒瑞医药2018 2570 25.5 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Hengrui ... 2,570" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
恒瑞医药2019 3321 29.2 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Jiangsu Hengrui Medicine ... 3,321" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
恒瑞医药2020 4022 21.1 B 27,735 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入 277.35亿元" = 27735 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
恒瑞医药2021 4017 -0.1 B 25,906 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入 259.06亿元" = 25906 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
恒瑞医药2022 3167 -21.1 B 21,275 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入 212.75亿元" = 21275 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
恒瑞医药2023 3225 1.8 B 22,820 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入 228.20亿元" = 22820 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
恒瑞医药2024 3889 20.6 B 27,985 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入 279.85亿元" = 27985 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
恒瑞医药2025 4401 13.2 B 31,629 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入 316.29亿元" = 31629 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
惠氏2000 10200 – C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
惠氏2001 10900 6.9 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
惠氏2002 11400 4.6 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
惠氏2003 12600 10.5 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
惠氏2004 13900 10.3 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
惠氏2005 15000 7.9 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
惠氏2006 16300 8.7 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
惠氏2007 17900 9.8 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
惠氏2008 18300 2.2 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
拜耳2000 3601 – C 3,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2001 4119 14.4 C 4,600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2002 4916 19.3 C 5,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2003 6338 28.9 C 5,600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2004 7339 15.8 C 5,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2005 7841 6.8 C 6,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2006 11304 44.2 C 9,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 9000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2007 14532 28.6 C 10,600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2008 14999 3.2 C 10,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2009 14490 -3.4 C 10,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2010 13674 -5.6 C 10,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2011 14477 5.9 C 10,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2012 14150 -2.3 C 11,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
拜耳2013 15594 10.2 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 15,594" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
拜耳2014 16351 4.9 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 16,351" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
拜耳2015 15558 -4.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 15,558" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
拜耳2016 16886 8.5 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 16,886" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
拜耳2017 17544 3.9 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 17,544" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
拜耳2018 18221 3.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 18,221" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
拜耳2019 18610 2.1 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 18,610" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
拜耳2020 18995 2.1 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
拜耳2021 20119 5.9 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
拜耳2022 18898 -6.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
拜耳2023 17663 -6.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
拜耳2024 17710 0.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
拜耳2025 19188 8.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
新基2003 271 – B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
新基2004 377 39.1 B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
新基2005 537 42.4 B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
新基2006 899 67.4 B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
新基2007 1406 56.4 B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
新基2008 2160 53.6 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
2600 / (1+20.1%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
新基2009 2600 20.4 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
celgene 2.6 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
新基2010 3626 39.5 B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
新基2011 4700 29.6 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
celgene $4.7 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
新基2012 5506 17.1 B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
新基2013 6359 15.5 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Celgene ... 6,359" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
新基2014 7476 17.6 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Celgene ... 7,476" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
新基2015 9069 21.3 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Celgene ... 9,069" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
新基2016 11114 22.5 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Celgene ... 11,114" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
新基2017 12928 16.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Celgene ... 12,928" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
新基2018 15238 17.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Celgene ... 15,238" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
施维雅2000 2216 – C 2,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2001 2328 5.1 C 2,600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2002 2647 13.7 C 2,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2003 3395 28.3 C 3,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2004 3980 17.2 C 3,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2005 4232 6.3 C 3,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2006 4647 9.8 C 3,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2007 5347 15.0 C 3,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2008 6029 12.8 C 4,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2009 5434 -9.9 C 3,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2010 5178 -4.7 C 3,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2011 5707 10.2 C 4,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2012 5403 -5.3 C 4,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
施维雅2013 5058 -6.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Servier ... 5,058" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
施维雅2014 5999 18.6 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Servier ... 5,999" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
施维雅2015 4470 -25.5 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Servier ... 4,470" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
施维雅2016 4167 -6.8 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Servier ... 4,167" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
施维雅2017 4566 9.6 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Servier ... 4,566" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
施维雅2018 5103 11.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Servier ... 5,103" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
施维雅2019 4658 -8.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"LES LABORATOIRES SERVIER ... 4,658" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
施维雅2020 5155 10.7 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
施维雅2021 4344 -15.7 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
施维雅2022 5193 19.5 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
施维雅2023 5113 -1.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
施维雅2024 5262 2.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
施维雅2025 5440 3.4 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
明治制果药业2019 6353 – B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Meiji Holdings ... 6,353" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
晖致2020 11495 – B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
晖致2021 17508 52.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
晖致2022 15999 -8.6 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
晖致2023 15228 -4.8 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
晖致2024 14534 -4.6 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
晖致2025 14090 -3.1 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
普渡制药2013 2217 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Purdue ... 2,217" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
普瑞高2022 5436 – B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
梯瓦2000 1200 – C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1200 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2001 1700 41.7 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2002 2500 47.1 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2003 3300 32.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2004 3900 18.2 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2005 5300 35.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2006 8400 58.5 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 8400 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2007 9400 11.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 9400 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2008 11100 18.1 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11100 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2009 13900 25.2 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 13900 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2010 16100 15.8 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 16100 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2011 18300 13.7 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2012 20300 10.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 20300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
梯瓦2013 17563 -13.5 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva ... 17,563" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
梯瓦2014 17474 -0.5 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva ... 17,474" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
梯瓦2015 16982 -2.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva ... 16,982" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
梯瓦2016 18462 8.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva ... 18,462" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
梯瓦2017 18261 -1.1 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva ... 18,261" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
梯瓦2018 13122 -28.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva ... 13,122" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
梯瓦2019 11090 -15.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva Pharmaceutical Industries ... 11,090" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
梯瓦2020 11009 -0.7 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
梯瓦2021 10468 -4.9 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
梯瓦2022 12071 15.3 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
梯瓦2023 12500 3.6 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
梯瓦2024 13495 8.0 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
梯瓦2025 14077 4.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
森林实验室2008 3460 – B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
3600 / (1+3.9%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
森林实验室2009 3600 4.0 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
forest 3.6 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn; Forest fiscal year to March
森林实验室2011 4200 – B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
forest $4.2 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn; Forest fiscal year to March
森林实验室2013 3380 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Forest Laboratories ... 3,380" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
欧加隆2021 6172 – B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
欧加隆2022 6038 -2.2 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
欧加隆2023 6142 1.7 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
欧加隆2024 6219 1.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
欧加隆2025 6060 -2.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
武田2000 7504 – C 828,524 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 963,400 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
武田2001 6919 -7.8 C 864,352 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,005,060 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
武田2002 7387 6.8 C 899,630 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,046,081 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
武田2003 8288 12.2 C 934,331 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,086,431 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
武田2004 9035 9.0 B 970,500 JPY m phx_takeda_seg+fx_fed_h10 FY2005 (Mar 2005) results, segment split
Pharmaceutical business net sales (iyaku jigyo)Pharmaceutical business net sales (iyaku jigyo)
Pharmaceutical 970.5 bn yen (86%), other 152.5 bn (14%); total 1,122,960
Segment figure as quoted in a web-search result for the FY2005 results announcement; the announcement itself not opened. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
武田2005 9220 2.1 C 1,042,498 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,212,207 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
武田2006 9599 4.1 C 1,122,444 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,305,167 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
武田2007 10385 8.2 C 1,182,330 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,374,802 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
武田2008 13220 27.3 C 1,322,969 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,538,336 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
武田2009 13592 2.8 C 1,260,730 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,465,965 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
武田2010 14282 5.1 C 1,220,671 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,419,385 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
武田2011 16445 15.1 C 1,297,682 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,508,932 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
武田2012 13591 -17.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 13,591" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
武田2014 13038 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 13,038" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
武田2015 12565 -3.6 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 12,565" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
武田2016 12773 1.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 12,773" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
武田2017 13577 6.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 13,577" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
武田2018 17427 28.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 17,427" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
武田2019 29747 70.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 29,747" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
武田2020 27896 -6.2 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
武田2021 29605 6.1 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
武田2022 29690 0.3 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
武田2023 27687 -6.7 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
武田2024 29782 7.6 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
武田2025 29671 -0.4 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
沃森制药2008 1770 – B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
2000 / (1+13.1%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
沃森制药2009 2000 13.0 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
watson 2.0 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
沃森制药2011 3700 – B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
watson $3.7 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
法玛西亚2000 15000 – C phx_est selected data / segment note
Pharmaceutical sales (Pharmacia incl. Searle; merged into...Pharmaceutical sales (Pharmacia incl. Searle; merged into Pfizer Apr 2003)
Pharmacia sales excl. consumer healthcare and animal health, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
法玛西亚2001 14300 -4.7 C phx_est selected data / segment note
Pharmaceutical sales (Pharmacia incl. Searle; merged into...Pharmaceutical sales (Pharmacia incl. Searle; merged into Pfizer Apr 2003)
Pharmacia sales excl. consumer healthcare and animal health, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
法玛西亚2002 13800 -3.5 C phx_est selected data / segment note
Pharmaceutical sales (Pharmacia incl. Searle; merged into...Pharmaceutical sales (Pharmacia incl. Searle; merged into Pfizer Apr 2003)
Pharmacia sales excl. consumer healthcare and animal health, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
浙江医药2000 133 – B 1,104 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 110,449.29" (10,000 CNY) = 1,104.49 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2001 105 -21.3 B 869 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 86,862.82" (10,000 CNY) = 868.63 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2002 135 28.6 B 1,117 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 111,701.21" (10,000 CNY) = 1,117.01 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2003 138 1.9 B 1,138 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 113,847.14" (10,000 CNY) = 1,138.47 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2004 168 21.8 B 1,387 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 138,682.97" (10,000 CNY) = 1,386.83 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2005 231 37.7 B 1,890 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 189,001.58" (10,000 CNY) = 1,890.02 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2006 276 19.6 B 2,199 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 219,922.61" (10,000 CNY) = 2,199.23 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2007 290 5.3 B 2,209 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 220,882.56" (10,000 CNY) = 2,208.83 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2008 542 86.4 B 3,761 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 376,102.93" (10,000 CNY) = 3,761.03 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2009 612 13.1 B 4,184 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 418,374.08" (10,000 CNY) = 4,183.74 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2010 673 10.0 B 4,558 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 455,826.52" (10,000 CNY) = 4,558.27 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2011 747 10.9 B 4,826 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 482,596.84" (10,000 CNY) = 4,825.97 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2012 834 11.7 B 5,264 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 526,400.61" (10,000 CNY) = 5,264.01 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2013 802 -3.8 B 4,933 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 493,292.02" (10,000 CNY) = 4,932.92 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2014 784 -2.2 B 4,832 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 483,229.18" (10,000 CNY) = 4,832.29 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2015 716 -8.8 B 4,497 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 449,666.24" (10,000 CNY) = 4,496.66 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2016 795 11.1 B 5,279 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 527,920.40" (10,000 CNY) = 5,279.20 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2017 843 6.0 B 5,693 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 569,258.04" (10,000 CNY) = 5,692.58 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
浙江医药2018 1039 23.3 B 6,859 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 68.59亿元" = 6859 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
浙江医药2019 1020 -1.8 B 7,044 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 70.44亿元" = 7044 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
浙江医药2020 1063 4.2 B 7,327 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 73.27亿元" = 7327 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
浙江医药2021 1415 33.2 B 9,129 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 91.29亿元" = 9129 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
浙江医药2022 1208 -14.6 B 8,116 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 81.16亿元" = 8116 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
浙江医药2023 1102 -8.8 B 7,794 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 77.94亿元" = 7794 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
浙江医药2024 1303 18.3 B 9,375 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 93.75亿元" = 9375 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
浙江医药2025 1236 -5.2 B 8,881 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 88.81亿元" = 8881 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
海正药业2000 63 – B 518 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 51,823.65" (10,000 CNY) = 518.24 m
Sina Finance table for stock 600267.
海正药业2001 70 11.6 B 578 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 57,821.17" (10,000 CNY) = 578.21 m
Sina Finance table for stock 600267.
海正药业2002 92 32.0 B 763 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 76,308.32" (10,000 CNY) = 763.08 m
Sina Finance table for stock 600267.
海正药业2003 187 103.4 B 1,552 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 155,178.61" (10,000 CNY) = 1,551.79 m
Sina Finance table for stock 600267.
海正药业2004 215 14.8 B 1,781 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 178,075.12" (10,000 CNY) = 1,780.75 m
Sina Finance table for stock 600267.
海正药业2005 234 8.6 B 1,914 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 191,357.52" (10,000 CNY) = 1,913.58 m
Sina Finance table for stock 600267.
海正药业2006 286 22.5 B 2,280 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 228,026.78" (10,000 CNY) = 2,280.27 m
Sina Finance table for stock 600267.
海正药业2007 373 30.5 B 2,839 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 283,877.07" (10,000 CNY) = 2,838.77 m
Sina Finance table for stock 600267.
海正药业2008 458 22.7 B 3,182 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 318,197.83" (10,000 CNY) = 3,181.98 m
Sina Finance table for stock 600267.
海正药业2009 586 27.9 B 4,003 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 400,347.04" (10,000 CNY) = 4,003.47 m
Sina Finance table for stock 600267.
海正药业2010 671 14.6 B 4,545 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 454,450.90" (10,000 CNY) = 4,544.51 m
Sina Finance table for stock 600267.
海正药业2011 799 19.0 B 5,161 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 516,139.42" (10,000 CNY) = 5,161.39 m
Sina Finance table for stock 600267.
海正药业2012 920 15.2 B 5,802 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 580,176.61" (10,000 CNY) = 5,801.77 m
Sina Finance table for stock 600267.
海正药业2013 1400 52.2 B 8,604 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 860,431.16" (10,000 CNY) = 8,604.31 m
Sina Finance table for stock 600267.
海正药业2014 1639 17.1 B 10,097 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 1,009,674.79" (10,000 CNY) = 10,096.75 m
Sina Finance table for stock 600267.
海正药业2015 1396 -14.9 B 8,767 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 876,742.81" (10,000 CNY) = 8,767.43 m
Sina Finance table for stock 600267.
海正药业2016 1466 5.0 B 9,733 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 973,342.35" (10,000 CNY) = 9,733.42 m
Sina Finance table for stock 600267.
海正药业2017 1565 6.8 B 10,572 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 1,057,152.67" (10,000 CNY) = 10,571.53 m
Sina Finance table for stock 600267.
海正药业2018 1543 -1.4 B 10,187 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 101.87亿元" = 10187 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
海正药业2019 1604 3.9 B 11,072 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 110.72亿元" = 11072 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
海正药业2020 1647 2.7 B 11,354 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 113.54亿元" = 11354 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
海正药业2021 1794 9.0 B 11,572 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 115.72亿元" = 11572 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
海正药业2022 1694 -5.6 B 11,379 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 113.79亿元" = 11379 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
海正药业2023 1421 -16.1 B 10,053 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 100.53亿元" = 10053 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
海正药业2024 1437 1.1 B 10,340 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 103.40亿元" = 10340 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
海正药业2025 1468 2.2 B 10,550 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 105.50亿元" = 10550 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
渤健2008 2840 – B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
3200 / (1+12.6%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
渤健2009 3200 12.7 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
biogen 3.2 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
渤健2011 3800 – B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
biogen $3.8 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
渤健2013 5429 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 5,429" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
渤健2014 8203 51.1 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 8,203" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
渤健2015 9189 12.0 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 9,189" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
渤健2016 9818 6.8 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 9,818" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
渤健2017 10355 5.5 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 10,355" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
渤健2018 10887 5.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 10,887" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
渤健2019 11380 4.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 11,380" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
渤健2020 10692 -6.0 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
渤健2021 8847 -17.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
渤健2022 7988 -9.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
渤健2023 7247 -9.3 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
渤健2024 7215 -0.4 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
渤健2025 7119 -1.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
灵北2000 297 – C 2,400 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2001 372 25.2 C 3,100 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2002 458 23.0 C 3,600 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3600 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2003 655 43.0 C 4,300 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4300 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2004 836 27.7 C 5,000 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5000 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2005 1002 19.9 C 6,000 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6000 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2006 1196 19.3 C 7,100 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7100 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2007 1509 26.2 C 8,200 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 8200 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2008 1913 26.8 C 9,700 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 9700 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2009 2208 15.4 C 11,800 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11800 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2010 2442 10.6 C 13,700 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 13700 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2011 2914 19.3 C 15,600 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 15600 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2012 2938 0.8 C 17,000 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17000 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
灵北2013 2431 -17.2 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Lundbeck ... 2,431" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
灵北2014 2223 -8.6 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Lundbeck ... 2,223" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
爱可泰隆2016 2448 – B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Actelion ... 2,448" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
爵士制药2021 3079 – B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
爵士制药2022 3634 18.0 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
爵士制药2023 3737 2.8 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
爵士制药2024 3821 2.2 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
爵士制药2025 4022 5.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
瑞迪博士实验室2007 1247 – B 50,006 INR m phx_drl_20f+fx_fed_h10 Form 20-F FY2012, selected data (IFRS)
Total revenues (IFRS)Total revenues (IFRS)
revenues 50,006 (Rs m)
Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business.
瑞迪博士实验室2008 1522 22.0 B 69,441 INR m phx_drl_20f+fx_fed_h10 Form 20-F FY2012, selected data (IFRS)
Total revenues (IFRS)Total revenues (IFRS)
revenues 69,441 (Rs m)
Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business.
瑞迪博士实验室2009 1485 -2.4 B 70,277 INR m phx_drl_20f+fx_fed_h10 Form 20-F FY2012, selected data (IFRS)
Total revenues (IFRS)Total revenues (IFRS)
revenues 70,277 (Rs m)
Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business.
瑞迪博士实验室2010 1642 10.6 B 74,693 INR m phx_drl_20f+fx_fed_h10 Form 20-F FY2012, selected data (IFRS)
Total revenues (IFRS)Total revenues (IFRS)
revenues 74,693 (Rs m)
Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business.
瑞迪博士实验室2011 2029 23.5 B 96,737 INR m phx_drl_20f+fx_fed_h10 Form 20-F FY2012, selected data (IFRS)
Total revenues (IFRS)Total revenues (IFRS)
revenues 96,737 (Rs m)
Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business.
瑞迪博士实验室2023 3007 – B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
瑞迪博士实验室2024 3304 9.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
田边三菱制药2005 3607 – B 407,800 JPY m phx_mtpc+fx_fed_h10 article text
Combined sales of Mitsubishi Pharma + Tanabe Seiyaku (pro...Combined sales of Mitsubishi Pharma + Tanabe Seiyaku (pro forma, practically all pharma)
combined sales totaled 407.8 billion yen in the year to March 2006
Seen only as a search snippet; the two merged in Oct 2007.
田边三菱制药2011 5160 – B 407,156 JPY m phx_mtpc_credit+fx_fed_h10 credit report text
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
Yen 419,179 million, 3% up from Yen 407,156 million in the previous term
Third-party credit report (snippet); FY2007-2010 not found.
田边三菱制药2012 3505 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe ... 3,505" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
田边三菱制药2014 2928 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe ... 2,928" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
田边三菱制药2015 2542 -13.2 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe ... 2,542" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
田边三菱制药2016 2696 6.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe ... 2,696" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
田边三菱制药2017 2581 -4.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe ... 2,581" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
田边三菱制药2018 2913 12.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe ... 2,913" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
田边三菱制药2019 2822 -3.1 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe Pharma ... 2,822" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
田边三菱制药2020 3106 10.1 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
百时美施贵宝2000 13000 – C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
百时美施贵宝2001 14000 7.7 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
百时美施贵宝2002 14200 1.4 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
百时美施贵宝2003 15200 7.0 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
百时美施贵宝2004 14600 -3.9 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
百时美施贵宝2005 14500 -0.7 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
百时美施贵宝2006 14900 2.8 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
百时美施贵宝2007 15900 6.7 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
百时美施贵宝2008 17690 11.3 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
18800 / (1+6.3%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
百时美施贵宝2009 18800 6.3 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
bms 18.8 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
百时美施贵宝2010 19500 3.7 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
百时美施贵宝2011 21200 8.7 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
bms $21.2 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
百时美施贵宝2012 17600 -17.0 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
百时美施贵宝2013 12306 -30.1 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 12,306" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
百时美施贵宝2014 11969 -2.7 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 11,969" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
百时美施贵宝2015 14480 21.0 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 14,480" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
百时美施贵宝2016 18163 25.4 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 18,163" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
百时美施贵宝2017 19258 6.0 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 19,258" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
百时美施贵宝2018 21581 12.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 21,581" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
百时美施贵宝2019 40689 88.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 40,689" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
百时美施贵宝2020 41903 3.0 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
百时美施贵宝2021 45669 9.0 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
百时美施贵宝2022 45417 -0.6 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
百时美施贵宝2023 44398 -2.2 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
百时美施贵宝2024 47821 7.7 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
百时美施贵宝2025 47748 -0.2 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
百济神州2024 3789 – B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
百济神州(BeOne)2025 5282 – B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
百深(Baxalta)2015 6148 – B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Baxalta ... 6,148" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
百特2008 5320 – B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
5600 / (1+5.2%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
百特2009 5600 5.3 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
baxter 5.6 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
百特2011 6100 – B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
baxter $6.1 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
百特2013 8265 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Baxter ... 8,265" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
百特2014 8694 5.2 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Baxter ... 8,694" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
益普生2018 2628 – B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ipsen ... 2,628" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
益普生2019 2884 9.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ipsen ... 2,884" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
益普生2020 2962 2.7 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
益普生2021 3236 9.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
益普生2022 3447 6.5 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
益普生2023 3555 3.1 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
益普生2024 3708 4.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
益普生2025 4155 12.1 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
盐野义制药2003 1707 – C 192,384 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 200,400 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
盐野义制药2004 1781 4.4 C 191,328 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 199,300 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
盐野义制药2005 1667 -6.4 C 188,448 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 196,300 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
盐野义制药2006 1639 -1.6 C 191,712 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 199,700 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
盐野义制药2007 1807 10.2 C 205,697 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 214,268 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
盐野义制药2008 2182 20.8 C 218,411 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 227,511 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
盐野义制药2009 2883 32.1 C 267,362 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 278,502 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
盐野义制药2010 3171 10.0 C 271,056 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 282,350 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
盐野义制药2011 3252 2.5 C 256,584 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 267,275 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
石药集团2009 774 – C 6,000 HKD m phx_cn_cspc+phx_cn_est+fx_fed_h10 Financial Summary (p.120)
Estimated revenue of the full CSPC pharmaceutical group (...Estimated revenue of the full CSPC pharmaceutical group (HK$)
Listed vehicle revenue HK$ 1,296.3 m (before the late-2012 injection of the parent's Shijiazhuang businesses); 2013 group = 9,949 m, back-cast at roughly 10-15% a year
The AR2012/AR2014 summaries show only the small listed vehicle (HK$1.3-4.1 bn, marked 'Note') for 2009-2012; the operating group was much larger, so a back-cast from 2013 is used. Replace with CSPC Holdings / Shijiazhuang Pharma Group figures if found. Grade C.
石药集团2010 850 9.8 C 6,600 HKD m phx_cn_cspc+phx_cn_est+fx_fed_h10 Financial Summary (p.120)
Estimated revenue of the full CSPC pharmaceutical group (...Estimated revenue of the full CSPC pharmaceutical group (HK$)
Listed vehicle revenue HK$ 1,757.6 m (before the late-2012 injection of the parent's Shijiazhuang businesses); 2013 group = 9,949 m, back-cast at roughly 10-15% a year
The AR2012/AR2014 summaries show only the small listed vehicle (HK$1.3-4.1 bn, marked 'Note') for 2009-2012; the operating group was much larger, so a back-cast from 2013 is used. Replace with CSPC Holdings / Shijiazhuang Pharma Group figures if found. Grade C.
石药集团2011 964 13.4 C 7,500 HKD m phx_cn_cspc+phx_cn_est+fx_fed_h10 Financial Summary (p.120)
Estimated revenue of the full CSPC pharmaceutical group (...Estimated revenue of the full CSPC pharmaceutical group (HK$)
Listed vehicle revenue HK$ 2,407.4 m (before the late-2012 injection of the parent's Shijiazhuang businesses); 2013 group = 9,949 m, back-cast at roughly 10-15% a year
The AR2012/AR2014 summaries show only the small listed vehicle (HK$1.3-4.1 bn, marked 'Note') for 2009-2012; the operating group was much larger, so a back-cast from 2013 is used. Replace with CSPC Holdings / Shijiazhuang Pharma Group figures if found. Grade C.
石药集团2012 1109 15.1 C 8,600 HKD m phx_cn_cspc+phx_cn_est+fx_fed_h10 Financial Summary (p.120)
Estimated revenue of the full CSPC pharmaceutical group (...Estimated revenue of the full CSPC pharmaceutical group (HK$)
Listed vehicle revenue HK$ 4,146.4 m (before the late-2012 injection of the parent's Shijiazhuang businesses); 2013 group = 9,949 m, back-cast at roughly 10-15% a year
The AR2012/AR2014 summaries show only the small listed vehicle (HK$1.3-4.1 bn, marked 'Note') for 2009-2012; the operating group was much larger, so a back-cast from 2013 is used. Replace with CSPC Holdings / Shijiazhuang Pharma Group figures if found. Grade C.
石药集团2013 1283 15.7 B 9,949 HKD m phx_cn_cspc+fx_fed_h10 Financial Summary
Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)
Revenue 9,949,103 (HK$'000)
HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified.
石药集团2014 1413 10.1 B 10,955 HKD m phx_cn_cspc+fx_fed_h10 Financial Summary
Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)
Revenue 10,955,077 (HK$'000)
HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified.
石药集团2015 1470 4.0 B 11,394 HKD m phx_cn_cspc+fx_fed_h10 consolidated statement of profit or loss, 2015 comparative (via search summary)
Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)
Revenue HK$11,393.7 m
HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified.
石药集团2016 1593 8.4 B 12,369 HKD m phx_cn_cspc+fx_fed_h10 consolidated statement of profit or loss (via search summary)
Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)
Revenue HK$12,369.0 m
HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified.
石药集团2017 1984 24.5 B 15,463 HKD m phx_cn_cspc+fx_fed_h10 turnover chart in the 2018 report (via search summary)
Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)
about HK$15,463 m
HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified.
石药集团2018 2683 35.2 B 21,029 HKD m phx_cn_cspc_res+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
"revenue HK$21,029 million, +36.0%"
HK$ as originally reported (restated to RMB 17,716.5 m in the 2019 report)
石药集团2019 3201 19.3 B 22,103 CNY m phx_cn_cspc_res+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
"Revenue RMB22,103 million, +24.8%"
Reporting currency changed to RMB from 2019
石药集团2020 3617 13.0 B 24,942 CNY m phx_cn_cspc_res+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
"revenue +12.8% to RMB24,942 million"
Annual results
石药集团2021 4321 19.4 B 27,867 CNY m phx_cn_cspc_res+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
"+11.7% to RMB27,867 million"
Matches company filing quoted in search
石药集团2022 4606 6.6 B 30,937 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
Revenue FY2022 30,937
Third-party table (S&P Global data)
石药集团2023 4445 -3.5 B 31,450 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
Revenue FY2023 31,450
Third-party table (S&P Global data)
石药集团2024 4032 -9.3 B 29,009 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
Revenue FY2024 29,009
Third-party table; another aggregator shows 27,758
石药集团2025 3619 -10.2 B 26,006 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
Revenue FY2025 26,006
Third-party table; audited FY2025 results published March 2026
礼来2000 10862 – B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
礼来2001 11543 6.3 B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
礼来2002 11078 -4.0 B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
礼来2003 12583 13.6 B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
礼来2004 13858 10.1 B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
礼来2005 14645 5.7 B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
礼来2006 15691 7.1 B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
礼来2007 17200 9.6 C phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
礼来2008 19330 12.4 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
21200 / (1+9.7%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
礼来2009 21200 9.7 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
lilly 21.2 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
礼来2010 21700 2.4 C phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
礼来2011 21900 0.9 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
lilly $21.9 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
礼来2012 20500 -6.4 C phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
礼来2013 20119 -1.9 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 20,119" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
礼来2014 16349 -18.7 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 16,349" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
礼来2015 15792 -3.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 15,792" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
礼来2016 17173 8.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 17,173" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
礼来2017 18532 7.9 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 18,532" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
礼来2018 19580 5.7 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 19,580" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
礼来2019 20085 2.6 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 20,085" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
礼来2020 22646 12.8 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
礼来2021 25958 14.6 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
礼来2022 25463 -1.9 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
礼来2023 31868 25.2 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
礼来2024 40716 27.8 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
礼来2025 60777 49.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
福泰制药2018 3038 – B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Vertex ... 3,038" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
福泰制药2019 4161 37.0 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Vertex Pharmaceuticals ... 4,161" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
福泰制药2020 6203 49.1 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
福泰制药2021 7573 22.1 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
福泰制药2022 8607 13.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
福泰制药2023 9869 14.7 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
福泰制药2024 11020 11.7 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
福泰制药2025 11971 8.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
科伦药业2007 267 – B 2,029 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 202,932.66" (10,000 CNY) = 2,029.33 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
科伦药业2008 377 41.4 B 2,621 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 262,139.13" (10,000 CNY) = 2,621.39 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
科伦药业2009 475 25.9 B 3,246 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 324,598.53" (10,000 CNY) = 3,245.99 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
科伦药业2010 595 25.2 B 4,026 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 402,640.00" (10,000 CNY) = 4,026.40 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
科伦药业2011 797 33.9 B 5,148 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 514,784.88" (10,000 CNY) = 5,147.85 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
科伦药业2012 933 17.1 B 5,885 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 588,527.86" (10,000 CNY) = 5,885.28 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
科伦药业2013 1111 19.1 B 6,831 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 683,128.20" (10,000 CNY) = 6,831.28 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
科伦药业2014 1302 17.2 B 8,023 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 802,342.13" (10,000 CNY) = 8,023.42 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
科伦药业2015 1236 -5.1 B 7,763 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 776,334.00" (10,000 CNY) = 7,763.34 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
科伦药业2016 1290 4.4 B 8,566 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 856,594.34" (10,000 CNY) = 8,565.94 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
科伦药业2017 1693 31.2 B 11,435 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 1,143,494.88" (10,000 CNY) = 11,434.95 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
科伦药业2018 2477 46.3 B 16,352 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 163.52亿元" = 16352 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
科伦药业2019 2554 3.1 B 17,636 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 176.36亿元" = 17636 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
科伦药业2020 2388 -6.5 B 16,464 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 164.64亿元" = 16464 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
科伦药业2021 2679 12.2 B 17,277 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 172.77亿元" = 17277 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
科伦药业2022 2834 5.8 B 19,038 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 190.38亿元" = 19038 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
科伦药业2023 3032 7.0 B 21,454 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 214.54亿元" = 21454 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
科伦药业2024 3031 0.0 B 21,812 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 218.12亿元" = 21812 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
科伦药业2025 2576 -15.0 B 18,513 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 185.13亿元" = 18513 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
第一三共2005 8189 – B 925,918 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 925,918
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
第一三共2006 7949 -2.9 B 929,506 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 929,506
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
第一三共2007 7731 -2.7 B 880,120 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 880,120
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
第一三共2008 8415 8.9 B 842,147 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 842,147
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
第一三共2009 10265 22.0 B 952,105 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 952,105
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
第一三共2010 11318 10.3 B 967,365 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 967,365
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
第一三共2011 11896 5.1 B 938,677 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 938,677
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
第一三共2012 10268 -13.7 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 10,268" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
第一三共2014 7575 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 7,575" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
第一三共2015 7215 -4.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 7,215" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
第一三共2016 7535 4.4 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 7,535" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
第一三共2017 7358 -2.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 7,358" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
第一三共2018 7033 -4.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 7,033" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
第一三共2019 7942 12.9 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 7,942" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
第一三共2020 8029 1.1 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
第一三共2021 7261 -9.6 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
第一三共2022 7089 -2.4 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
第一三共2023 8091 14.1 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
第一三共2024 10912 34.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
第一三共2025 12039 10.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
第一制药(日本)2002 2643 – A 321,926 JPY m phx_daiichi_20f+fx_fed_h10 Form 20-F FY2005, consolidated statements of income
Consolidated net sales (pure-play pharma)Consolidated net sales (pure-play pharma)
net sales 321,926 (yen m)
Read from the income statement; the Selected Financial Data section (FY2001-02) not reached.
第一制药(日本)2003 2865 8.4 A 322,977 JPY m phx_daiichi_20f+fx_fed_h10 Form 20-F FY2005, consolidated statements of income
Consolidated net sales (pure-play pharma)Consolidated net sales (pure-play pharma)
net sales 322,977 (yen m)
Read from the income statement; the Selected Financial Data section (FY2001-02) not reached.
第一制药(日本)2004 3024 5.6 A 324,860 JPY m phx_daiichi_20f+fx_fed_h10 Form 20-F FY2005, consolidated statements of income
Consolidated net sales (pure-play pharma)Consolidated net sales (pure-play pharma)
net sales 324,860 (yen m)
Read from the income statement; the Selected Financial Data section (FY2001-02) not reached.
罗氏2000 8946 – C 15,100 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 15100 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2001 10139 13.3 C 17,100 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17100 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2002 12178 20.1 C 18,900 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18900 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2003 13911 14.2 C 18,700 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18700 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2004 16514 18.7 C 20,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 20500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2005 19690 19.2 C 24,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 24500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2006 23548 19.6 C 29,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 29500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2007 28362 20.4 C 34,000 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 34000 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2008 33791 19.1 C 36,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 36500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2009 35345 4.6 C 38,300 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 38300 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2010 35096 -0.7 C 36,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 36500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2011 37869 7.9 C 33,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 33500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2012 37888 0.0 C 35,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 35500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
罗氏2013 39143 3.3 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 39,143" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
罗氏2014 40086 2.4 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 40,086" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
罗氏2015 38733 -3.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 38,733" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
罗氏2016 39552 2.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 39,552" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
罗氏2017 41732 5.5 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 41,732" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
罗氏2018 44552 6.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 44,552" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
罗氏2019 48247 8.3 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 48,247" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
罗氏2020 47492 -1.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
罗氏2021 49293 3.8 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
罗氏2022 47909 -2.8 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
罗氏2023 49110 2.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
罗氏2024 52457 6.8 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
罗氏2025 57514 9.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
美纳里尼2000 1016 – C 1,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2001 1075 5.8 C 1,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2002 1229 14.4 C 1,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2003 1584 28.9 C 1,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2004 1866 17.8 C 1,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2005 1991 6.7 C 1,600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2006 2135 7.2 C 1,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2007 2468 15.6 C 1,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2008 3235 31.1 C 2,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2009 3344 3.4 C 2,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2010 3717 11.2 C 2,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2011 4176 12.3 C 3,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2012 4116 -1.4 C 3,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
美纳里尼2013 3324 -19.2 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 3,324" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
美纳里尼2014 3442 3.5 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 3,442" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
美纳里尼2015 2836 -17.6 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 2,836" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
美纳里尼2016 2916 2.8 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 2,916" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
美纳里尼2017 3072 5.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 3,072" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
美纳里尼2018 3313 7.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 3,313" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
美纳里尼2019 3233 -2.4 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 3,233" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
美纳里尼2020 3465 7.2 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
美纳里尼2021 3616 4.4 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
美纳里尼2022 3621 0.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
美纳里尼2023 3840 6.0 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
美纳里尼2024 4006 4.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
美纳里尼2025 4358 8.8 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
美达(Meda)2015 2139 – B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Meda ... 2,139" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
艾伯维2013 18790 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 18,790" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
艾伯维2014 19879 5.8 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 19,879" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
艾伯维2015 22724 14.3 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 22,724" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
艾伯维2016 25299 11.3 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 25,299" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
艾伯维2017 27743 9.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 27,743" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
艾伯维2018 32067 15.6 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 32,067" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
艾伯维2019 32351 0.9 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 32,351" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
艾伯维2020 44341 37.1 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
艾伯维2021 55041 24.1 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
艾伯维2022 56179 2.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
艾伯维2023 52734 -6.1 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
艾伯维2024 54484 3.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
艾伯维2025 58271 7.0 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
艾尔健(Actavis)2013 7206 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Actavis ... 7,206" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
艾尔健(Actavis)2014 11130 54.5 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Actavis ... 11,130" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
艾尔建2002 1425 – C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
艾尔建2003 1771 24.3 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
艾尔建2004 2045 15.5 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
艾尔建2005 2319 13.4 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
艾尔建2006 2600 12.1 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
艾尔建2007 3200 23.1 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
艾尔建2008 3510 9.7 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
3700 / (1+5.3%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
艾尔建2009 3700 5.4 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
allergan 3.7 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
艾尔建2010 4000 8.1 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
艾尔建2011 4400 10.0 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
allergan $4.4 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
艾尔建2012 5000 13.6 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
艾尔建2013 5398 8.0 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 5,398" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
艾尔建2014 6234 15.5 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 6,234" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
艾尔建2015 18403 195.2 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 18,403" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
艾尔建2016 18597 1.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 18,597" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
艾尔建2017 14906 -19.8 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 14,906" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
艾尔建2018 14700 -1.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 14,700" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
艾尔建2019 15153 3.1 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 15,153" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
艾尔建2020 4774 -68.5 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
莫德纳2021 19167 – B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
莫德纳2022 18435 -3.8 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
莫德纳2023 6671 -63.8 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
莫德纳2024 3218 -51.8 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
葛兰素史克2000 22889 – C 15,100 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 15100 GBP m
2000 = group turnover ~18,079 less Consumer Healthcare ~3,000
葛兰素史克2001 24776 8.2 B 17,205 GBP m phx_gsk20f2005+fx_fed_h10 Financial record, Pharmaceuticals turnover (UK GAAP)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Pharmaceuticals turnover 17205 GBP m (as relayed by search summary of 20-F FY2005)
UK GAAP; 2003 IFRS equivalent about 18,114; read via search summary, not the table itself
葛兰素史克2002 27036 9.1 B 17,995 GBP m phx_gsk20f2005+fx_fed_h10 Financial record, Pharmaceuticals turnover (UK GAAP)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Pharmaceuticals turnover 17995 GBP m (as relayed by search summary of 20-F FY2005)
UK GAAP; 2003 IFRS equivalent about 18,114; read via search summary, not the table itself
葛兰素史克2003 29612 9.5 B 18,114 GBP m phx_gsk20f2005+fx_fed_h10 Financial record, Pharmaceuticals turnover (UK GAAP)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Pharmaceuticals turnover 18114 GBP m (as relayed by search summary of 20-F FY2005)
UK GAAP; 2003 IFRS equivalent about 18,114; read via search summary, not the table itself; IFRS-restated 2003 = 18,114
葛兰素史克2004 31337 5.8 C 17,100 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17100 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
葛兰素史克2005 33960 8.4 C 18,661 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18661 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
葛兰素史克2006 37412 10.2 C 20,300 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 20300 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
葛兰素史克2007 39433 5.4 C 19,700 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 19700 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
葛兰素史克2008 39637 0.5 C 21,400 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 21400 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
葛兰素史克2009 38191 -3.6 C 24,400 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 24400 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
葛兰素史克2010 37890 -0.8 C 24,500 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 24500 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
葛兰素史克2011 38007 0.3 C 23,700 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 23700 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
葛兰素史克2012 35199 -7.4 C 22,200 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 22200 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
葛兰素史克2013 33055 -6.1 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 33,055" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
葛兰素史克2014 30302 -8.3 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 30,302" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
葛兰素史克2015 27051 -10.7 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 27,051" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
葛兰素史克2016 27775 2.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 27,775" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
葛兰素史克2017 28668 3.2 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 28,668" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
葛兰素史克2018 30645 6.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 30,645" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
葛兰素史克2019 31288 2.1 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 31,288" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
葛兰素史克2020 30585 -2.2 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
葛兰素史克2021 33443 9.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
葛兰素史克2022 38254 14.4 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
葛兰素史克2023 36758 -3.9 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
葛兰素史克2024 39718 8.1 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
葛兰素史克2025 42717 7.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
诺华2000 11000 – C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺华2001 12300 11.8 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 12300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺华2002 14000 13.8 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 14000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺华2003 17500 25.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺华2004 19800 13.1 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 19800 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺华2005 22400 13.1 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 22400 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺华2006 27300 21.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 27300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺华2007 32646 19.6 B phx_nov20f2007 Item 4 principal markets tables
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Pharmaceuticals 24,025 + Sandoz 7,169 + Vaccines and Diagnostics 1,452 = 32,646 (US$ m)
Sum of three divisions from the 20-F FY2007
诺华2008 35500 8.7 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 35500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺华2009 38000 7.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 38000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺华2010 41000 7.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 41000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺华2011 44000 7.3 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 44000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺华2012 44500 1.1 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 44500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺华2013 46017 3.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 46,017" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
诺华2014 46127 0.2 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 46,127" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
诺华2015 42467 -7.9 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 42,467" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
诺华2016 41554 -2.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 41,554" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
诺华2017 41875 0.8 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 41,875" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
诺华2018 43481 3.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 43,481" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
诺华2019 46085 6.0 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 46,085" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
诺华2020 47202 2.4 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
诺华2021 51128 8.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
诺华2022 50079 -2.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
诺华2023 52473 4.8 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
诺华2024 50191 -4.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
诺华2025 54332 8.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
诺和诺德2000 2218 – C 17,900 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17900 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2001 2607 17.5 C 21,700 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 21700 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2002 3091 18.6 C 24,300 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 24300 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2003 4020 30.1 C 26,400 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 26400 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2004 4731 17.7 C 28,300 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 28300 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2005 5262 11.2 C 31,500 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 31500 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2006 5894 12.0 C 35,000 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 35000 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2007 7121 20.8 C 38,700 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 38700 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2008 8873 24.6 C 45,000 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 45000 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2009 9556 7.7 C 51,078 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 51078 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2010 10833 13.4 C 60,776 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 60776 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2011 12394 14.4 C 66,346 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 66346 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2012 13483 8.8 C 78,026 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 78026 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
诺和诺德2013 14886 10.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 14,886" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
诺和诺德2014 15825 6.3 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 15,825" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
诺和诺德2015 16054 1.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 16,054" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
诺和诺德2016 16610 3.5 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 16,610" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
诺和诺德2017 16971 2.2 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 16,971" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
诺和诺德2018 17726 4.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 17,726" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
诺和诺德2019 18296 3.2 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 18,296" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
诺和诺德2020 19444 6.3 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
诺和诺德2021 22417 15.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
诺和诺德2022 25384 13.2 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
诺和诺德2023 33722 32.8 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
诺和诺德2024 42122 24.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
诺和诺德2025 46801 11.1 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
费森尤斯2013 3604 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius ... 3,604" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
费森尤斯2014 3707 2.9 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius ... 3,707" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
费森尤斯2015 3709 0.1 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius ... 3,709" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
费森尤斯2016 3753 1.2 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius ... 3,753" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
费森尤斯2017 4070 8.4 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius ... 4,070" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
费森尤斯2018 4328 6.3 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius ... 4,328" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
费森尤斯2019 4224 -2.4 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius Kabi ... 4,224" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
费森尤斯2020 4221 -0.1 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
费森尤斯2021 4224 0.1 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
费森尤斯2022 4342 2.8 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
费森尤斯2023 4538 4.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
费森尤斯2024 4810 6.0 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
费森尤斯2025 5206 8.2 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
赛诺菲2004 17787 – C 14,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 14300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赛诺菲2005 33606 88.9 C 27,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 27000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赛诺菲2006 35544 5.8 C 28,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 28300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赛诺菲2007 38385 8.0 C 28,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 28000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赛诺菲2008 39702 3.4 C 27,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 27000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赛诺菲2009 40822 2.8 C 29,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 29300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赛诺菲2010 40359 -1.1 C 30,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 30400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赛诺菲2011 46494 15.2 C 33,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 33400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赛诺菲2012 44894 -3.4 C 34,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 34900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赛诺菲2013 37701 -16.0 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 37,701" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
赛诺菲2014 38223 1.4 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 38,223" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
赛诺菲2015 34896 -8.7 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 34,896" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
赛诺菲2016 34174 -2.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 34,174" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
赛诺菲2017 34078 -0.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 34,078" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
赛诺菲2018 35121 3.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 35,121" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
赛诺菲2019 34924 -0.6 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 34,924" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
赛诺菲2020 35802 2.5 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
赛诺菲2021 38934 8.7 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
赛诺菲2022 40353 3.6 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
赛诺菲2023 40805 1.1 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
赛诺菲2024 44243 8.4 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
赛诺菲2025 48971 10.7 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
赛诺菲-圣德拉堡2000 4155 – C 4,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-Synthelabo net sales (pure-play pharma)Sanofi-Synthelabo net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赛诺菲-圣德拉堡2001 4836 16.4 C 5,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-Synthelabo net sales (pure-play pharma)Sanofi-Synthelabo net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赛诺菲-圣德拉堡2002 6145 27.1 C 6,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-Synthelabo net sales (pure-play pharma)Sanofi-Synthelabo net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赛诺菲-圣德拉堡2003 8375 36.3 C 7,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-Synthelabo net sales (pure-play pharma)Sanofi-Synthelabo net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
赫力昂2025 3599 – B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
赫士睿2013 2759 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Hospira ... 2,759" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
赫士睿2014 3035 10.0 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Hospira ... 3,035" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
赫士睿2015 2131 -29.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Hospira ... 2,131" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
辉凌2016 2134 – B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ferring ... 2,134" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
辉凌2017 2243 5.1 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ferring ... 2,243" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
辉凌2018 2461 9.7 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ferring ... 2,461" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
辉瑞2000 24400 – C phx_est selected data / segment note
Pharmaceutical segment, approx. (total revenues less cons...Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)
Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
辉瑞2001 26800 9.8 C phx_est selected data / segment note
Pharmaceutical segment, approx. (total revenues less cons...Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)
Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
辉瑞2002 27100 1.1 C phx_est selected data / segment note
Pharmaceutical segment, approx. (total revenues less cons...Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)
Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
辉瑞2003 39425 45.5 B phx_sec_pfe2005 Financial Review, Human Health revenue table p.12
Human Health segment revenues (includes Pharmacia from Ap...Human Health segment revenues (includes Pharmacia from Apr 2003)
Human Health 2003 39,425 (total revenues 44,736)
Pfizer 2005 Financial Report (Exhibit 13 to FY2005 10-K)
辉瑞2004 46133 17.0 B phx_sec_pfe2005 Financial Review, Human Health revenue table p.12
Human Health segment revenuesHuman Health segment revenues
Human Health 2004 46,133 (total revenues 52,516)
Pfizer 2005 Financial Report (Exhibit 13 to FY2005 10-K)
辉瑞2005 44284 -4.0 B phx_sec_pfe2005 Financial Review, Human Health revenue table p.12
Human Health segment revenuesHuman Health segment revenues
Human Health 2005 44,284 (total revenues 51,298)
Pfizer 2005 Financial Report (Exhibit 13 to FY2005 10-K)
辉瑞2006 45100 1.8 C phx_est selected data / segment note
Pharmaceutical segment, approx. (total revenues less cons...Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)
Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
辉瑞2007 44400 -1.6 C phx_est selected data / segment note
Pharmaceutical segment, approx. (total revenues less cons...Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)
Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
辉瑞2008 44210 -0.4 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
45400 / (1+2.7%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
辉瑞2009 45400 2.7 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
pfizer 45.4 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn; Pfizer excludes Wyeth, which is its own entity until absorbed
辉瑞2010 58500 28.9 B phx_pe2011 Pharm Exec 50 (2011): Pfizer 2010 Rx sales
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
"grew from $45.4 billion in Rx sales to $58.5 billion"
2010 includes Wyeth; read from a search-result summary of the 12th Pharm Exec 50 (page not retrievable)
辉瑞2011 57700 -1.4 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
pfizer $57.7 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
辉瑞2012 48000 -16.8 C phx_est selected data / segment note
Pharmaceutical segment, approx. (total revenues less cons...Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)
Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
辉瑞2013 45011 -6.2 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 45,011" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
辉瑞2014 44514 -1.1 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 44,514" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
辉瑞2015 43112 -3.1 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 43,112" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
辉瑞2016 45906 6.5 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 45,906" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
辉瑞2017 45345 -1.2 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 45,345" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
辉瑞2018 45302 -0.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 45,302" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
辉瑞2019 43662 -3.6 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 43,662" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
辉瑞2020 35608 -18.4 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
辉瑞2021 72043 102.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
辉瑞2022 91303 26.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
辉瑞2023 48218 -47.2 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
辉瑞2024 51953 7.7 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
辉瑞2025 49909 -3.9 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
迈蓝2008 4310 – B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
4800 / (1+11.4%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
迈蓝2009 4800 11.4 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
mylan 4.8 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
迈蓝2010 5450 13.5 C phx_est selected data / segment note
Total revenues (generics)Total revenues (generics)
Mylan total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
迈蓝2011 5500 0.9 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
mylan $5.5 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
迈蓝2012 6800 23.6 C phx_est selected data / segment note
Total revenues (generics)Total revenues (generics)
Mylan total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
迈蓝2013 6772 -0.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 6,772" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
迈蓝2014 7585 12.0 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 7,585" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
迈蓝2015 9291 22.5 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 9,291" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
迈蓝2016 10839 16.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 10,839" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
迈蓝2017 11454 5.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 11,454" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
迈蓝2018 11144 -2.7 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 11,144" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
迈蓝2019 11200 0.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 11,200" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
远藤国际2014 2238 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Endo ... 2,238" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
远藤国际2015 2856 27.6 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Endo ... 2,856" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
远藤国际2016 4010 40.4 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Endo ... 4,010" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
远藤国际2017 3469 -13.5 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Endo ... 3,469" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
远藤国际2018 2947 -15.0 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Endo ... 2,947" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
远藤国际2019 2887 -2.0 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Endo International ... 2,887" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
远藤国际2020 2897 0.3 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
远藤国际2021 2990 3.2 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
阿拉宾度制药2019 2787 – B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Aurobindo Pharma ... 2,787" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
阿拉宾度制药2020 3000 7.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
阿拉宾度制药2021 3159 5.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
阿斯利康2000 15500 – C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 15500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2001 16480 6.3 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 16480 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2002 17841 8.3 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17841 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2003 18849 5.6 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18849 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2004 21426 13.7 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 21426 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2005 23950 11.8 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 23950 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2006 26475 10.5 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 26475 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2007 29559 11.6 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 29559 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2008 31601 6.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 31601 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2009 32804 3.8 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 32804 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2010 33269 1.4 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 33269 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2011 33591 1.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 33591 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2012 27973 -16.7 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 27973 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
阿斯利康2013 24523 -12.3 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 24,523" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
阿斯利康2014 25694 4.8 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 25,694" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
阿斯利康2015 23264 -9.5 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 23,264" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
阿斯利康2016 20967 -9.9 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 20,967" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
阿斯利康2017 19782 -5.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 19,782" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
阿斯利康2018 20671 4.5 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 20,671" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
阿斯利康2019 23207 12.3 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 23,207" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
阿斯利康2020 25518 10.0 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
阿斯利康2021 36131 41.6 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
阿斯利康2022 42998 19.0 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
阿斯利康2023 43790 1.8 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
阿斯利康2024 50946 16.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
阿斯利康2025 55038 8.0 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
阿斯本制药2013 2710 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Aspen ... 2,710" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
阿斯本制药2014 3066 13.1 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Aspen ... 3,066" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
阿斯本制药2015 2586 -15.7 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Aspen ... 2,586" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
阿斯本制药2016 2403 -7.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Aspen ... 2,403" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
阿斯本制药2017 2591 7.8 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Aspen ... 2,591" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
雀巢健康科学2015 2431 – B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Nestle ... 2,431" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
雅培2000 7300 – C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
雅培2001 7900 8.2 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
雅培2002 8500 7.6 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
雅培2003 9300 9.4 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
雅培2004 10000 7.5 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
雅培2005 10800 8.0 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
雅培2006 11600 7.4 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
雅培2007 12800 10.3 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
雅培2008 14300 11.7 C phx_est Segment note
Pharmaceutical Products segment (est.)Pharmaceutical Products segment (est.)
Pharm Exec 2009 15.6 bn; its change column (-6.7%) would imply 16.7 bn for 2008, which does not fit the 10-K segment (about 14 bn)
Estimate from memory of the segment figure; the Pharm Exec derived 2008 value is not used because FX/perimeter makes it inconsistent with the segment
雅培2009 15600 9.1 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
abbott 15.6 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
雅培2010 19100 22.4 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
雅培2011 22400 17.3 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
abbott $22.4 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
雅培2012 22900 2.2 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
雅培2013 4974 -78.3 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott ... 4,974" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
雅培2014 5101 2.6 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott ... 5,101" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
雅培2015 3720 -27.1 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott ... 3,720" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
雅培2016 3859 3.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott ... 3,859" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
雅培2017 4287 11.1 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott ... 4,287" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
雅培2018 4422 3.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott ... 4,422" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
雅培2019 4486 1.4 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott Laboratories ... 4,486" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
雅培2020 4486 0.0 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
雅培2021 4692 4.6 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
雅培2022 4885 4.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
雅培2023 5039 3.2 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
雅培2024 5166 2.5 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
雅培2025 5508 6.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
雪兰诺2000 770 – C 1,300 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
雪兰诺2001 949 23.2 C 1,600 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1600 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
雪兰诺2002 1160 22.3 C 1,800 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
雪兰诺2003 1637 41.1 C 2,200 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2200 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
雪兰诺2004 1933 18.1 C 2,400 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
雪兰诺2005 2009 3.9 C 2,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
雪兰诺2006 2155 7.3 C 2,700 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2700 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
马林克罗2014 2310 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mallinckrodt ... 2,310" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
马林克罗2015 2976 28.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mallinckrodt ... 2,976" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
马林克罗2016 2918 -1.9 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mallinckrodt ... 2,918" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
马林克罗2017 3141 7.6 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mallinckrodt ... 3,141" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
马林克罗2018 2543 -19.0 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mallinckrodt ... 2,543" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
鲁宾2016 2490 – B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Lupin ... 2,490" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
鲁宾2017 2344 -5.9 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Lupin ... 2,344" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
默克集团2000 1754 – C 1,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2001 1881 7.2 C 2,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2002 2269 20.6 C 2,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2003 2716 19.7 C 2,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2004 3358 23.7 C 2,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2005 3485 3.8 C 2,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2006 3642 4.5 C 2,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2007 7814 114.5 C 5,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2008 8823 12.9 C 6,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2009 8499 -3.7 C 6,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2010 9028 6.2 C 6,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2011 10023 11.0 C 7,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2012 9648 -3.7 C 7,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
默克集团2013 7913 -18.0 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 7,913" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
默克集团2014 7683 -2.9 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 7,683" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
默克集团2015 7693 0.1 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 7,693" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
默克集团2016 6633 -13.8 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 6,633" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
默克集团2017 6880 3.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 6,880" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
默克集团2018 7001 1.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 7,001" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
默克集团2019 7516 7.4 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 7,516" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
默克集团2020 7579 0.8 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
默克集团2021 8392 10.7 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
默克集团2022 8366 -0.3 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
默克集团2023 8711 4.1 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
默克集团2024 9148 5.0 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
默克集团2025 9728 6.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
默沙东2000 19700 – C phx_est selected data / segment note
Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-Medco
Merck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
默沙东2001 21200 7.6 C phx_est selected data / segment note
Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-Medco
Merck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
默沙东2002 21446 1.2 B phx_sec_mrk2006 FY2006 10-K Item 6 selected financial data
Total sales (Merck Rx incl. vaccines; Medco spun off Aug ...Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)
Sales 21,445.8
Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8)
默沙东2003 22486 4.8 B phx_sec_mrk2006 FY2005 Exhibit 13 income statement
Total sales (Merck Rx incl. vaccines; Medco spun off Aug ...Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)
Sales 22,485.9
Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8)
默沙东2004 22939 2.0 B phx_sec_mrk2006 FY2005 Exhibit 13 income statement
Total sales (Merck Rx incl. vaccines; Medco spun off Aug ...Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)
Sales 22,938.6
Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8)
默沙东2005 22012 -4.0 B phx_sec_mrk2006 FY2006 10-K Item 1 product sales table
Total sales (Merck Rx incl. vaccines; Medco spun off Aug ...Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)
Sales 22,011.9
Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8)
默沙东2006 22636 2.8 B phx_sec_mrk2006 FY2006 10-K Item 1 product sales table
Total sales (Merck Rx incl. vaccines; Medco spun off Aug ...Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)
Sales 22,636.0
Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8)
默沙东2007 24200 6.9 C phx_est selected data / segment note
Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-Medco
Merck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
默沙东2008 23570 -2.6 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
25200 / (1+6.9%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
默沙东2009 25200 6.9 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
merck 25.2 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn; Merck includes Schering-Plough from Nov 2009
默沙东2010 39500 56.7 C phx_est selected data / segment note
Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-Medco
Merck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
默沙东2011 41300 4.6 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
merck $41.3 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
默沙东2012 40500 -1.9 C phx_est selected data / segment note
Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-Medco
Merck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
默沙东2013 37519 -7.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 37,519" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
默沙东2014 36607 -2.4 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 36,607" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
默沙东2015 35244 -3.7 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 35,244" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
默沙东2016 35563 0.9 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 35,563" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
默沙东2017 35370 -0.5 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 35,370" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
默沙东2018 37353 5.6 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 37,353" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
默沙东2019 40903 9.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 40,903" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
默沙东2020 41435 1.3 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
默沙东2021 43259 4.4 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
默沙东2022 49627 14.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
默沙东2023 50846 2.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
默沙东2024 54314 6.8 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
默沙东2025 54685 0.7 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
中外制药FY2001 – – uncertain 203000 JPY https://the-shashi.com/tse/4519/finan...
Fiscal year ended March until 2002, then December after t...Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). FY2000 and FY2001 are both 203,000 in the source: suspicious, so FY2001 is kept out of the chart. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
中国生物制药2008 – – uncertain 2282 HKD https://www1.hkexnews.hk/listedco/lis...
Currency (HKD vs RMB) taken from a search summary, not ch...Currency (HKD vs RMB) taken from a search summary, not checked in the document; left uncertain.
中国生物制药2009 – – uncertain 3244 HKD https://www1.hkexnews.hk/listedco/lis...
Currency (HKD vs RMB) taken from a search summary, not ch...Currency (HKD vs RMB) taken from a search summary, not checked in the document; left uncertain.
中国生物制药2010 – – uncertain 4086 HKD https://www1.hkexnews.hk/listedco/lis...
Currency (HKD vs RMB) taken from a search summary, not ch...Currency (HKD vs RMB) taken from a search summary, not checked in the document; left uncertain.
中国生物制药2011 – – uncertain 5782 HKD https://www1.hkexnews.hk/listedco/lis...
Currency (HKD vs RMB) taken from a search summary, not ch...Currency (HKD vs RMB) taken from a search summary, not checked in the document; left uncertain.
山之内制药FY1999/00 – – missing –
Yamanouchi sales for FY1999/00 and FY2000/01 not found in...Yamanouchi sales for FY1999/00 and FY2000/01 not found in the sources reached.
山之内制药FY2000/01 – – missing –
Yamanouchi sales for FY1999/00 and FY2000/01 not found in...Yamanouchi sales for FY1999/00 and FY2000/01 not found in the sources reached.
藤泽药品工业FY1999/00 – – missing –
Fujisawa Pharmaceutical consolidated sales not found in t...Fujisawa Pharmaceutical consolidated sales not found in the sources reached.
藤泽药品工业FY2000/01 – – missing –
Fujisawa Pharmaceutical consolidated sales not found in t...Fujisawa Pharmaceutical consolidated sales not found in the sources reached.
藤泽药品工业FY2001/02 – – missing –
Fujisawa Pharmaceutical consolidated sales not found in t...Fujisawa Pharmaceutical consolidated sales not found in the sources reached.
藤泽药品工业FY2002/03 – – missing –
Fujisawa Pharmaceutical consolidated sales not found in t...Fujisawa Pharmaceutical consolidated sales not found in the sources reached.
藤泽药品工业FY2003/04 – – missing –
Fujisawa Pharmaceutical consolidated sales not found in t...Fujisawa Pharmaceutical consolidated sales not found in the sources reached.
藤泽药品工业FY2004/05 – – missing –
Fujisawa Pharmaceutical consolidated sales not found in t...Fujisawa Pharmaceutical consolidated sales not found in the sources reached.
三共FY1999/00 – – missing –
Sankyo pharma sales not found except the FY2004/05 deriva...Sankyo pharma sales not found except the FY2004/05 derivation.
三共FY2000/01 – – missing –
Sankyo pharma sales not found except the FY2004/05 deriva...Sankyo pharma sales not found except the FY2004/05 derivation.
三共FY2001/02 – – missing –
Sankyo pharma sales not found except the FY2004/05 deriva...Sankyo pharma sales not found except the FY2004/05 derivation.
三共FY2002/03 – – missing –
Sankyo pharma sales not found except the FY2004/05 deriva...Sankyo pharma sales not found except the FY2004/05 derivation.
三共FY2003/04 – – missing –
Sankyo pharma sales not found except the FY2004/05 deriva...Sankyo pharma sales not found except the FY2004/05 derivation.
第一制药(日本)FY1999/00 – – missing –
Selected Financial Data section of the 20-F not reached.Selected Financial Data section of the 20-F not reached.
第一制药(日本)FY2000/01 – – missing –
Selected Financial Data section of the 20-F not reached.Selected Financial Data section of the 20-F not reached.
第一制药(日本)FY2001/02 – – missing –
Selected Financial Data section of the 20-F not reached.Selected Financial Data section of the 20-F not reached.
盐野义制药FY1999/00 – – missing –
Aggregator values for FY2000-2003 (412,600 / 420,100 / 28...Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,200) are far above Shionogi's ~200 bn and not credible; not used.
盐野义制药FY2000/01 – – missing –
Aggregator values for FY2000-2003 (412,600 / 420,100 / 28...Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,200) are far above Shionogi's ~200 bn and not credible; not used.
盐野义制药FY2001/02 – – missing –
Aggregator values for FY2000-2003 (412,600 / 420,100 / 28...Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,200) are far above Shionogi's ~200 bn and not credible; not used.
盐野义制药FY2002/03 – – missing –
Aggregator values for FY2000-2003 (412,600 / 420,100 / 28...Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,200) are far above Shionogi's ~200 bn and not credible; not used.
小野制药FY1999/00 – – missing –
Not found.Not found.
小野制药FY2000/01 – – missing –
Not found.Not found.
大冢FY1999/00 – – missing –
Pre-2003 table is non-consolidated and not comparable.Pre-2003 table is non-consolidated and not comparable.
大冢FY2000/01 – – missing –
Pre-2003 table is non-consolidated and not comparable.Pre-2003 table is non-consolidated and not comparable.
大冢FY2001/02 – – missing –
Pre-2003 table is non-consolidated and not comparable.Pre-2003 table is non-consolidated and not comparable.
三菱制药FY1999/00 – – missing –
Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
三菱制药FY2000/01 – – missing –
Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
三菱制药FY2001/02 – – missing –
Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
三菱制药FY2002/03 – – missing –
Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
三菱制药FY2003/04 – – missing –
Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
三菱制药FY2004/05 – – missing –
Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
三菱制药FY2005/06 – – missing –
Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
田边制药FY1999/00 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
田边制药FY2000/01 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
田边制药FY2001/02 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
田边制药FY2002/03 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
田边制药FY2003/04 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
田边制药FY2004/05 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
田边制药FY2005/06 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
田边三菱制药FY2006/07 – – missing –
FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached.
田边三菱制药FY2007/08 – – missing –
FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached.
田边三菱制药FY2008/09 – – missing –
FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached.
田边三菱制药FY2009/10 – – missing –
FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached.
田边三菱制药FY2010/11 – – missing –
FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached.
协和麒麟2000 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
协和麒麟2001 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
协和麒麟2002 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
协和麒麟2003 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
协和麒麟2004 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
协和麒麟2005 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
协和麒麟2006 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
协和麒麟2007 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
协和麒麟2008 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
协和麒麟2009 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
瑞迪博士实验室FY1999/00 – – missing –
Not found in the sources reached.Not found in the sources reached.
瑞迪博士实验室FY2000/01 – – missing –
Not found in the sources reached.Not found in the sources reached.
瑞迪博士实验室FY2001/02 – – missing –
Not found in the sources reached.Not found in the sources reached.
瑞迪博士实验室FY2002/03 – – missing –
Not found in the sources reached.Not found in the sources reached.
瑞迪博士实验室FY2003/04 – – missing –
Not found in the sources reached.Not found in the sources reached.
瑞迪博士实验室FY2004/05 – – missing –
Not found in the sources reached.Not found in the sources reached.
瑞迪博士实验室FY2005/06 – – missing –
Not found in the sources reached.Not found in the sources reached.
瑞迪博士实验室FY2006/07 – – missing –
Not found in the sources reached.Not found in the sources reached.
兰伯西2000 – – missing –
Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only).
兰伯西2001 – – missing –
Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only).
兰伯西2002 – – missing –
Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only).
兰伯西2003 – – missing –
Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only).
兰伯西2004 – – missing –
Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only).
兰伯西2005 – – missing –
Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only).
兰伯西2006 – – missing –
Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only).
兰伯西2007 – – missing –
Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only).
太阳制药FY1999/00 – – missing –
Not found (FY2012: 2012-13 annual report ten-year table n...Not found (FY2012: 2012-13 annual report ten-year table not reached).
太阳制药FY2000/01 – – missing –
Not found (FY2012: 2012-13 annual report ten-year table n...Not found (FY2012: 2012-13 annual report ten-year table not reached).
太阳制药FY2011/12 – – missing –
Not found (FY2012: 2012-13 annual report ten-year table n...Not found (FY2012: 2012-13 annual report ten-year table not reached).
恒瑞医药2000 – – missing –
Not found.Not found.
恒瑞医药2001 – – missing –
Not found.Not found.
恒瑞医药2002 – – missing –
Not found.Not found.
恒瑞医药2003 – – missing –
Not found.Not found.
恒瑞医药2004 – – missing –
Not found.Not found.
恒瑞医药2005 – – missing –
Not found.Not found.
恒瑞医药2006 – – missing –
Not found.Not found.
恒瑞医药2007 – – missing –
Not found.Not found.
恒瑞医药2008 – – missing –
Not found.Not found.
恒瑞医药2009 – – missing –
Not found.Not found.
中国生物制药2000 – – missing –
Not found.Not found.
中国生物制药2001 – – missing –
Not found.Not found.
中国生物制药2002 – – missing –
Not found.Not found.
中国生物制药2003 – – missing –
Not found.Not found.
中国生物制药2004 – – missing –
Not found.Not found.
中国生物制药2005 – – missing –
Not found.Not found.
中国生物制药2006 – – missing –
Not found.Not found.
中国生物制药2007 – – missing –
Not found.Not found.
中国生物制药2012 – – missing –
Not found.Not found.
西普拉FY1999/00 – – missing –
Not searched within the call budget.Not searched within the call budget.
西普拉FY2000/01 – – missing –
Not searched within the call budget.Not searched within the call budget.
西普拉FY2001/02 – – missing –
Not searched within the call budget.Not searched within the call budget.
西普拉FY2002/03 – – missing –
Not searched within the call budget.Not searched within the call budget.
西普拉FY2003/04 – – missing –
Not searched within the call budget.Not searched within the call budget.
西普拉FY2004/05 – – missing –
Not searched within the call budget.Not searched within the call budget.
西普拉FY2005/06 – – missing –
Not searched within the call budget.Not searched within the call budget.
西普拉FY2006/07 – – missing –
Not searched within the call budget.Not searched within the call budget.
西普拉FY2007/08 – – missing –
Not searched within the call budget.Not searched within the call budget.
西普拉FY2008/09 – – missing –
Not searched within the call budget.Not searched within the call budget.
西普拉FY2009/10 – – missing –
Not searched within the call budget.Not searched within the call budget.
西普拉FY2010/11 – – missing –
Not searched within the call budget.Not searched within the call budget.
西普拉FY2011/12 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY1999/00 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY2000/01 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY2001/02 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY2002/03 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY2003/04 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY2004/05 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY2005/06 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY2006/07 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY2007/08 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY2008/09 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY2009/10 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY2010/11 – – missing –
Not searched within the call budget.Not searched within the call budget.
鲁宾FY2011/12 – – missing –
Not searched within the call budget.Not searched within the call budget.
国药集团2000 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
国药集团2001 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
国药集团2002 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
国药集团2003 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
国药集团2004 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
国药集团2005 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
国药集团2006 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
国药集团2007 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
国药集团2008 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
国药集团2009 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
国药集团2010 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
国药集团2011 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
国药集团2012 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2000 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2001 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2002 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2003 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2004 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2005 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2006 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2007 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2008 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2009 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2010 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2011 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
云南白药2012 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2000 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2001 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2002 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2003 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2004 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2005 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2006 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2007 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2008 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2009 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2010 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2011 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
石药集团2012 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2000 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2001 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2002 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2003 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2004 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2005 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2006 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2007 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2008 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2009 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2010 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2011 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华东医药2012 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2000 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2001 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2002 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2003 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2004 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2005 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2006 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2007 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2008 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2009 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2010 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2011 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
天士力2012 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2000 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2001 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2002 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2003 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2004 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2005 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2006 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2007 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2008 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2009 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2010 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2011 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
哈药集团2012 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2000 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2001 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2002 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2003 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2004 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2005 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2006 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2007 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2008 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2009 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2010 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2011 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
华北制药2012 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2000 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2001 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2002 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2003 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2004 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2005 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2006 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2007 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2008 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2009 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2010 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2011 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ第一制糖2012 – – missing –
Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
渤健2000 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
渤健2001 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
渤健2002 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
渤健2003 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
渤健2004 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
渤健2005 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
渤健2006 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
渤健2007 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
渤健2010 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
渤健2012 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
健赞2000 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
健赞2001 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
健赞2002 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
健赞2003 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
健赞2004 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
健赞2005 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
健赞2006 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
健赞2007 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
森林实验室2000 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
森林实验室2001 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
森林实验室2002 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
森林实验室2003 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
森林实验室2004 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
森林实验室2005 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
森林实验室2006 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
森林实验室2007 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
森林实验室2010 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
森林实验室2012 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
金制药2000 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
金制药2001 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
金制药2002 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
金制药2003 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
金制药2004 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
金制药2005 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
金制药2006 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
金制药2007 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
金制药2008 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
金制药2009 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
金制药2010 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
沃森制药2000 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
沃森制药2001 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
沃森制药2002 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
沃森制药2003 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
沃森制药2004 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
沃森制药2005 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
沃森制药2006 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
沃森制药2007 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
沃森制药2010 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
沃森制药2012 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
迈蓝2000 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
迈蓝2001 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
迈蓝2002 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
迈蓝2003 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
迈蓝2004 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
迈蓝2005 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
迈蓝2006 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
迈蓝2007 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
百特2000 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
百特2001 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
百特2002 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
百特2003 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
百特2004 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
百特2005 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
百特2006 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
百特2007 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
百特2010 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
百特2012 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
艾尔建2000 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
艾尔建2001 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
吉利德科学2000 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
吉利德科学2001 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
吉利德科学2003 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
新基2000 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
新基2001 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
新基2002 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
基因泰克2000 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
基因泰克2001 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
基因泰克2002 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
基因泰克2003 – – missing –
No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
国药集团2013 – – missing https://www1.hkexnews.hk/listedco/lis...
Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013...Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found.
国药集团2014 – – missing https://www1.hkexnews.hk/listedco/lis...
Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013...Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found.
国药集团2015 – – missing https://www1.hkexnews.hk/listedco/lis...
Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013...Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found.
国药集团2016 – – missing https://www1.hkexnews.hk/listedco/lis...
Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013...Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found.
国药集团2017 – – missing https://www1.hkexnews.hk/listedco/lis...
Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013...Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found.

数据核查

本工具所用的每一个营收数值及其出处文件。A级为公司报告的该业务营收;B级由报告数据推算或取自市场研究机构;C级为模型估算。标为不确定、缺失或below_100m(年收入不足1亿美元,即纳入门槛)的行不计入图表。